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1 Summary 
 
Pin1, a unique and highly conserved eukaryotic peptidyl-prolyl cis/trans isomerase 
(PPIase), plays important roles in cellular regulation. Due to its activity to switch the 
conformation of peptidyl-proline bonds in polypeptide chains, Pin1 operates as a 
binary switch - often in fate-determining pathways. Unlike other post-translational 
modifications, Pin1-mediated cis/trans isomerization activity represents a non-
covalent post-translational modification and is usually controlled by substrate 
phosphorylation. However, how Pin1 switches protein activities remains unclear. 
This study reveals that yeast Pin1 (Ess1) Pin1 acts as a polyubiquitylation 
switch and controls the degree of substrate ubiquitylation and thereby protein fates. 
Pin1 is directly linked to the OLE pathway, which controls Spt23, an NFκB-related 
transcription factor that is crucial for providing cells with unsaturated fatty acids 
(Hoppe et al., 2000; Rape et al., 2001; Piwko and Jentsch, 2006). Interestingly, this 
study reveals that high Pin1 activity results in low ubiquitylation of Spt23, which 
triggers Spt23 precursor processing and hence transcription factor activation. By 
contrast, reduced Pin1 activity triggers robust Spt23 precursor polyubiquitylation, 
subsequently leading to its complete elimination by ERAD. Moreover, Spt23 
phosphorylation of S/T-Pro sites is not only an essential prerequisite for Ess1 binding 
via its WW domain and PPIase activity, this work also shows that binding of Ess1 to 
Spt23 is stimulated by casein kinase 2 (CK2)-mediated phosphorylation of Spt23, 
coupling the isomerization activity to the tightly controlled activities of proline-directed 
kinases (and phosphatases).  
Additionally, this study shows that inhibition of Pin1 in vivo in mammalian cells 
changes the ubiquitylation status of the tumor suppressor p53 from 
mono/oligoubiquitylation, which is known to trigger nuclear export, to 
polyubiquitylation, which causes nuclear p53 degradation. Furthermore, establishing 
a p53 in vitro ubiquitylation system to assay the direct influence of Pin1 on p53 
ubiquitylation reveals that p53 polyubiquitylation is negatively correlated with the 
amount of Pin1 and that Mdm2 and Pin1 indeed exert opposing effects on p53 
polyubiquitylation.  
The discovery that Pin1 acts as a fate switch by controlling the degree of 
substrate ubiquitylation reveals a so far unrecognized role of this PPIase in the 
ubiquitin proteasome system (UPS). How Pin1 controls ubiquitylation is so far 
unclear, however, it most likely acts by altering the affinities of certain E3 ligases. 
This also suggests that the Pin1 toggle may affect the degree of substrate 
ubiquitylation and therefore fate in other pathways as well. 
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2 Introduction 
 
2.1 The ubiquitin proteasome system (UPS) 
 
The cellular proteome is in a dynamic state of synthesis and degradation. 
Intracellular protein half-lives vary from a few minutes to several hours for individual 
protein species in the same cell. Currently three major intracellular proteolytic 
systems are found in all eukaryotic cells: The endosomal/lysosomal system, the 
process of autophagy, which also involves the lysosome, and the ubiquitin 
proteasome system (UPS). The UPS is the principal non-lysosomal system for 
degrading cytosolic and nuclear proteins in the cell, serving both regulatory and 
quality control functions. It is instrumental to almost every aspect of cellular regulation 
including cell cycle control, immune response, transcriptional regulation and signal 
transduction. In order to act efficiently in these regulatory processes intracellular 
protein degradation must be highly specific.  
Cellular proteases often recognize substrates via sequence-specific motifs 
located close to the actual cleavage site. Unlike conventional site-specific proteases, 
the 26S proteasome acts on numerous substrates and has no apparent preference 
for a specific amino acid sequence in the substrate. In fact to avoid promiscuous 
protein degradation and to achieve specificity and fidelity in the UPS a specialized 
system evolved in all eukaryotic systems in which substrates are selected and 
marked with the small protein ubiquitin. Once modified with several ubiquitin moieties 
the tagged substrate is destined for degradation and targeted to the 26S proteasome 
independently of its primary amino acid sequence. At the 26S proteasome, a 2.5 
MDa multi-subunit protease with an inner cavity lined with a number of different 
proteolytic sites, the ubiquitin moieties are trimmed off and the protein is dragged into 
the barrel shaped cavity and degraded into small peptides (Figure 3). The specific 
molecular design of the proteasome provides efficient and processive peptide 
hydrolysis and in addition prevents unwanted degradation by sequestering the active 
proteolytic sites in the cavity. The covalent attachment of ubiquitin to a substrate 
constitutes a post-translational modification, which serves various purposes like 
protein degradation by the UPS or modulation of protein localization or protein 
function. 
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2.2 The ubiquitin-conjugating system 
 
Ubiquitin is a small, evolutionary highly conserved polypeptide of 76 amino acids that 
is abundantly found in all eukaryotic cells. Ubiquitin is covalently conjugated to target 
proteins via an isopeptide bond between its carboxy-terminal glycine and the epsilon-
amino group of lysine residues in substrate protein. In a first step ubiquitin is 
synthesized as a poly-ubiquitin fusion protein (Ubi4) or as a fusion protein to the N-
termini of ribosomal proteins (Ubi1, Ubi2, Ubi3). Thus, ubiquitylation requires the 
proteolytic processing of the carboxy-terminus of the ubiquitin precursor proteins to 
its monomeric form that ends with a double glycine motif, a process also called 
ubiquitin maturation (Rose and Warms, 1983; Pickart and Rose, 1985).  
The covalent attachment of ubiquitin to target substrates is orchestrated by an 
enzymatic cascade of at least three enzymes (Jentsch, 1992, Kerscher et al., 2006): 
E1 - ubiquitin activating enzyme, E2 - ubiquitin conjugating enzyme and E3 - ubiquitin 
protein ligase, where the E3 enzyme, which is largely responsible for the specificity of 
the reaction, associates with the substrate (Fang and Weissman, 2004; Hershko and 
Ciechanover, 1998; Pickart, 2001). After the initial ATP-dependent activation by an 
E1 ubiquitin-activating enzyme, the C-terminal carboxy group of ubiquitin is 
adenylated, this activated ubiquitin-AMP forms a high-energy thioester bond with an 
active cysteine (Cys) residue in E1, and is then transferred to a specific Cys residue 
of one of a family of E2 ubiquitin-conjugating enzymes (Ciechanover et al., 1982; 
Haas et al., 1982, Haas et al., 1983). The E3 ubiquitin-ligase plays then a pivotal role 
in the ubiquitin-conjugation machinery by recruiting the activated ubiquitin-E2-
thioester-linked complex, and simultaneously recognizing specific target proteins. It 
functions either facilitating/handing over or directly catalyzing the ubiquitin transfer. 
This finally results in forming a isopeptide bond between the C-terminal carboxy-
group in ubiquitin and in most cases the epsilon-amino group of an internal lysine or 
the N-terminus of their substrates (Hershko et al., 1986) (Figure 1). Once conjugated 
by this enzymatic cascade ubiquitin itself is often a target for further ubiquitylation 
reactions by using one of its 7 internal lysine residues and leads to the formation of 
polyubiquitin chains (Figure 2). Polyubiquitin-chain assembly is often a processive 
reaction that usually requires E1, E2 and E3. However, recent studies have shown 
that during chain elongation another class of proteins, the E4 enzymes, can catalyze 
an extension of the mono/oligoubiquitin chain and acts as an efficient chain 
elongation factor (Koegl et al., 1999; Hoppe et al., 2005). In some cases the initial 
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monoubiquitylation orchestered by the action of E1, E2 and E3 converts a substrate 
into its active state, which is e.g. involved in transcriptional regulation, DNA-Repair, 
endocytosis or intracellular transport. Inactivation can occur then by E4-dependent 
ubiquitin chain elongation that finally marks the substrate for subsequent proteasome 
dependent degradation. 
 
Figure 1. The ubiquitin-conjugation machinery. Schematic overview over the enzymatic 
cascade catalyzing the ubiquitylation reaction. A protein substrate is conjugated with a single 
ubiquitin moiety by the concerted action of E1, E2 and E3 enzymes (Initiation). Ub is first 
activated in an ATP-consuming reaction by an E1-Ub-activating enzyme and subsequently 
transferred to the active Cys of an E2-conjugating enzyme. With the aid of a third enzyme, 
called the E3-ubiquitin ligase, E2 catalyzes the transfer of (poly)ubiquitin onto the substrate 
that is destined for degradation. In some cases monoubiquitylation converts the substrate into 
its active state, which is involved in transcriptional regulation, DNA-Repair, endocytosis or 
intracellular transport. Inactivation occurs by E4-dependent ubiquitin chain 
elongation/assembly that marks the substrate for subsequent 26S dependent degradation. 
 
 
2.3 E3 ligases determine substrate specificity 
 
Specificity of substrate modification is largely conferred at the final step of the 
ubiquitylation cascade by the E3 ubiquitin ligase. The complexity of the E3 ligase is 
manifested by the fact that ubiquitin so far employs one to two E1 activating 
enzymes, dozens of E2 and numerous E3 enzymes to fulfill the conjugation 
requirements (Kaiser and Fon, 2007; Jin et al., 2007; Pelzer et al., 2007), unlike most 
other ubiquitin-like-proteins, which only utilize a single E1, E2, and a few E3 enzymes 
in the conjugation reaction. 
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E3 ubiquitin-ligases are generally classified based on the sequence homology 
of their E2-binding domain into the following two subclasses: the E3 ligases of the 
RING-type and the HECT (homologous to E6-AP carboxy-terminus) domain-
containing E3s.  Although unrelated in sequence or structure both enzymes are alike 
in their ability to establish selective substrate binding. 
In the case of RING-E3 mediated catalysis, ubiquitin is directly transferred 
from the E2 to the substrate. The RING-E3, in most cases a multisubunit complex, 
functions as an adaptor between the activated E2 and the substrate, in contrast to 
the HECT domain the RING finger forms no thiol-ester with ubiquitin. A smaller set of 
E3 enzymes contain a U-box, a degenerate version of the RING-finger, which 
achieves the same general fold, but without coordinating metal ions (Koegl et al., 
1999). HECT-E3s are quite unique among the E3 ligases, due to their intrinsic 
catalytic activity. In HECT-E3-mediated catalysis, ubiquitin is transferred from the E2 
to a cysteine in the HECT-E3 as a thiol-ester conjugate and then transferred to the 
substrate, which is bound by the HECT-E3 enzyme (Pickart, C.M., 2001) (Figure 1). 
Substrate specificity of HECT-type E3s is mediated by protein-protein interaction 
domains. The C2-WW-HECT E3 ligases likely represent the by far best characterized 
subgroup of HECT ligases, they are highly conserved from yeast to mammals and 
include the family of Nedd4/Nedd-like ubiquitin ligases (neural-precursor-cell-
expressed, developmentally down-regulated). There are nine members in humans, 
three in S. pombe and D. melanogaster, but only one Nedd4 homolog in S. 
cerevisiae: the Rsp5 enzyme. Rsp5, which is one of the best studied C2-WW-HECT 
E3 ligases is essential for viability and plays a crucial role in the regulation of many 
cellular processes including intracellular trafficking (Dupre et al., 2004; Horak, J., 
2003; Staub and Rotin, 2006; Miranda and Sorkin, 2007), mRNA export (Rodriguez 
et al., 2003) and most intriguing the regulated ubiquitin/proteasome dependent 
processing (RUP, Hoppe et al., 2000) of the transcription factors Spt23 (and Mga2), 
both structurally related to NFκB, in the essential OLE pathway (Hoppe et al., 2000; 
Rape et al., 2001; Piwko and Jentsch, 2006). 
The C2-WW-HECT E3s bear a common general modular structure composed 
of an N-terminal protein kinase C (PKC)-related C2 domain, known to function as a 
lipid-binding domain, two to four WW protein-interacting domains that recognize 
proline rich PPxY motifs (Rotin, 1998; Shcherbik et al., 2004), and the catalytic C-
terminal HECT domain (Schwarz et al., 1998).  
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Regulated protein-protein interaction renders the basis for cellular signal 
transduction, a widely used molecular handle ensuring specificity in these signaling 
events are phosphate groups that are covalently attached to either tyrosine (pY), 
serine or threonine (pS/T) residues by site specific kinases. Although phosphorylation 
is a very common post-translational modification, there is actually only a handful of 
signaling domains known that recognize phosphorylated proteins with sequence 
specificity (Yaffe et al., 2002). The WW protein-protein interaction domain is in fact 
one of these rare examples.  
WW domains are found in a variety of different proteins and are known to 
regulate cellular localization and substrate selectivity. The domain is highly 
conserved between species and consists of a small module of approximately 35 to 
40 amino acids. WW domain-containing proteins have been shown to bind 
predominantly proline-rich motifs. Based on the recognition motif, they can be 
classified into four groups: PPxY (where x is any amino acid) (Chen and Sudol, 1995) 
including Nedd4 and Rsp5, PPLP (Bedford er al., 1997), PR (Bedford et al., 1998, 
2000) and most interestingly the group IV WW domains, phosphoserine/threonine 
residues that precede a proline residue (pS/T-P) (Yaffe et al., 1997, Lu et al. 1999) 
including the peptidyl-prolyl cis/trans isomerase Pin1/Ess1. Interestingly there are 
certain substrates described that are targets for more than one WW domain binding 
protein; in fact it was demonstrated that the CTD of RNA Pol II is the target for 
various WW domain-binding proteins, including the peptidyl-prolyl isomerase Ess1 
and the WW-HECT-E3 ligase Rsp5, both essential proteins in S. cerevisiae (Wu et 
al., 2001).  
The UPS plays another fundamental role in protein quality control (PQC) by 
removing proteins that are misfolded and therefore unable to perform their 
designated functions. In the cytosol this process often seems to involve a specialized 
subset of molecular chaperones that directly cooperate with the UPS during protein 
quality control. In mammalian cells defective and aberrantly folded proteins of the 
cytosol are frequently recognized by Hsp70-Hsp90 chaperones that directly 
cooperates with CHIP, a chaperone associated E3 ligase to target proteins for 
ubiquitylation (Esser et al., 2004) that belongs to the U-box containing E3 ligases 
(Koegl et al., 1999). In contrast to misfolded proteins in the cytosol, proteins, which 
are translocated into the ER, and fail to fold or assemble properly, are subject to a 
proteolytic quality control pathway, termed "ER-associated degradation" or ERAD. 
The spatial separation between substrate selection and degradation in ERAD 
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requires substrate transport from the ER to the cytosol by a process termed 
dislocation where they are ultimately degraded by the cytosolic UPS (Sommer and 
Jentsch, 1993; Meusser et al., 2005). Interestingly, ERAD also requires the activity of 
the ubiquitin-selective segregase Cdc48Ufd1/Npl4 (Braun et al., 2002), suggesting that 
the retrograde transport of short-lived substrates might be driven through the action 
of the AAA-ATPase Cdc48Ufd1/Npl4 in conjunction with the proteasome.  
 
 
2.4 Regulation of ubiquitin conjugation 
 
Understanding the crosstalk between different types of post-translational 
modifications is fundamental in delineating complex cellular signaling cascades. 
Regulation of a proteinʼs function through a single modification is possible either 
through creating a new protein binding site, by abolishing protein protein interaction, 
or through allosteric effects. However, in many cases proteins are modified by 
multiple post-translational modifications. Hence a significant increase in informational 
content would be acquired if the different post-translational modifications would act in 
combination to serve as three-dimensional signal surfaces. Considering chromatin-
based information, the interplay of covalent post-translational histone modifications 
are eminent examples (Bhaumik et al., 2007; Probst et al., 2009). Particularly 
prominent are the numerous connections between phosphorylation and 
ubiquitylation, which can either act positively or negatively in both directions to 
regulate cellular processes  
The phosphorylation of serine/threonine (pS/T) or tyrosine (pY) residues is a 
dynamic and effective way to change protein fates and was also demonstrated to be 
a key in determining the interactions between E3 ligases and their substrates. It is 
therefore tempting to speculate that phosphorylation events not only play a role in 
substrate recognition but also in integrating multiple post-translational modifications 
into a signaling network. In fact the S. cerevisiae G2 cyclins Clb2, Clb3, or the Cdk 
inhibitor Sic1 are examples where phosphorylation is a prerequisite for subsequent 
substrate ubiquitylation, leading to a signal for the interaction with the corresponding 
SCF type E3 ligase (Willems et al., 2004). Activation of the “classical” NF-κB 
pathway for instance involves several phosphorylation and ubiquitylation events and 
converges on the IκB kinase (IKK) signalosome.  
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E3 ligase substrate recognition can as well be inhibited as a consequence of 
a post-phosphorylational event; e.g. binding of the E3 ligase Mdm2 to p53 is inhibited 
by phosphorylation of Ser15/Thr18 in direct response to genotoxic stress, which 
subsequently results in the stabilization of p53 (Clegg et al., 2008). In contrast to 
substrate phosphorylation, also E3 ligases themselves can be modified by 
phosphorylation and therefore change the affinity to bind a substrate, e.g. 
phosphorylation of the APC/C subunit cdc20 by protein kinase A (PKA; Searle et al., 
2004). Furthermore, ubiquitylation can also be regulated by phosphorylation-
mediated subcellular localization of substrates. In principle, phosphorylation can 
regulate access of an E3 ligase to its substrate through phosphorylation-dependent 
transport of either the target or the ligase between cellular compartments. p53 for 
instance, which is phosphorylated upon genotoxic stress, translocates to the nucleus 
to activate downstream targets (like p21) as an active transcription factor and can be 
polyubiquitylated by the E3 ligase Mdm2 and degraded by the proteasome in the 
nucleus. Furthermore monoubiquitylated p53 is a signal for nuclear export, a reaction 
carried out by the same E3 ligase Mdm2 (Li et al., 2003). Finally rather than 
phosphorylation regulates ubiquitylation, also protein kinase activity itself is regulated 
by ubiquitylation (Chen, Z.J., 2005).  
In most cases it still remains unclear how phosphorylation triggers substrate 
E3 interaction and how this signal is translated into different cellular fates. 
Phosphorylation may change the substrateʼs conformation, or create specific binding 
surfaces to allow binding of auxiliary factors. Phosphorylation might also change the 
accessibility of certain lysines for ubiquitylation or change the composition of 
polyubiquitin chain linkage. Furthermore, post-translational modifications of the 
substrate might lead to a change of E3 affinities, which may be important for some 
E3 ligases that do not seem to act processively, like yeast Rsp5 or Mdm2. Non-
processive E3s might need a higher affinity or a chain elongation factor (E4) for 
assembling a polyubiquitin chain and this could therefore be utilized as a mechanism 
for positively or negatively regulating the subsequent fate of the substrate by either 
complete degradation or proteasomal processing. 
A key feature of the UPS is that ubiquitylation (analogous to phosphorylation) 
is a reversible modification. Ubiquitin can be specifically and efficiently removed from 
the substrate by a class of proteins termed deubiquitylating enzymes (DUBs; Amerik 
and Hochstrasser., 2004). This activity serves to switch off ubiquitin signals or to shift 
between different modifications on the same internal lysine of ubiquitin (Hershko and 
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Chiechanover, 1998; Newton et al., 2008). The regulation of substrate ubiquitylation 
via DUBs was interestingly shown for the active transcription factor Spt23 (p90). The 
NFκB-related transcription factor is a substrate for the deubiquitylating enzyme of the 
ovarian tumor family protein Otu1, which antagonized the HECT E3 ligase Rsp5 and 
the E4 enzyme Ufd2, respectively (Rumpf and Jentsch, 2006). 
 
 
2.5 Ubiquitylation, linkage and substrate fate 
 
The fate of ubiquitylated proteins is determined by the type of ubiquitin modification, 
the lysine used for polyubiquitin chain formation and furthermore the length of a 
polyubiquitin chain. Recently, mass spectrometry experiments indicated that basically 
all seven internal lysines in ubiquitin can be used for forming polyubiquitin chains. 
Based on semi-quantitative data K48 linked ubiquitin chains seem to be most 
abundant, followed by K11, K63, K6, K27, K29 and K33 (Xu and Peng, 2006). 
Additionally, ubiquitin can also be attached to its N-terminus in a head-to-tail fashion 
(Peng et al., 2003; Kirisako et al., 2006; Tokunaga et al., 2009). Newer studies based 
on absolute quantification of ubiquitin (Ub-AQUA) now show that the most prevalent 
linkage types in whole cell yeast extracts are K48-linked and K63-linked chains, 
approximately equally abundant, followed by K29 (Matiuhin et al., 2008). Whereas 
there is also data suggesting mixed linkages in one chain resulting in so called 
„forked“ or „barbed“ ubiquitin chain formation (Peng et al., 2003; Tagwerker et al., 
2006). Remarkably, some auxiliary substrate processing factors are able to directly 
influence the degree of ubiquitylation; the E4 processivity factor Ufd2 for example 
seems to switch the type of ubiquitin linkage of a ubiquitin chain from K29-linked to 
K48-linked ubiquitin (Koegl et al. 1999; Saeki et al., 2004).
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Figure 2. Linkage and fate of ubiquitylated substrates. Different ubiquitin modifications 
have distinct functions, substrates can be modified with a single ubiquitin (mono-Ub), multiple 
single ubiquitins or with ubiquitin chains (poly-Ub) or short. Ubiquitin chains differ in structure 
and function, depending on what lysine of ubiquitin is used for chain formation. 
 
The type of ubiquitin modification, mono-, oligo-, or polyubiquitylation with 
different kinds of linkage formation, determines different fates of the substrate in a 
cellular context (Figure 2). Hence, one feature of the UPS is the need and the 
capability to recruit or recognize polyubiquitylated substrates. Once modified with a 
K48-linked polyubiquitin chain of at least four ubiquitins (Thrower et al., 2000), the 
substrate can either bind to intrinsic ubiquitin receptors in the 19S regulatory subunit 
of the proteasome in a direct way through Rpn10 and Rpn13 or to a ubiquitin adaptor 
factor that mediates the binding between the polyubiquitylated substrate and the 
proteasome, acting as a ubiquitin adaptor receptor (Rad23, Dsk2, and Ddi1) 
(Welchman et al., 2005; Matiuhin et al., 2008). In fact a recent report suggests that 
for most substrates the transfer to the proteasome depends on the sequential action 
of ubiquitin binding factors (Rad23, Dsk2) that work in a hand-over mechanism to 
escort the ubiquitylated substrate on its way to the 26S (Richly et al., 2005).  
The most extensively studied function of the proteasome in cells is the 
complete and irreversible elimination of specific cellular proteins tagged with a K48-
linked polyubiquitin chain. In fact, as proteasomal degradation seems to be 
processive, it usually leads to the complete degradation of substrates once they have 
encountered the active sites of the inner cavity. However, emerging studies identified 
a growing number of cellular proteins with versatile functions that use ubiquitylation in 
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a non-proteolytic fashion. Addition of mono-ubiquitin, multiple mono-ubiquitin or 
modification with polyubiquitin chains through internal K63 linked ubiquitin are 
considered as non-canonical modifications that normally do not lead to subsequent 
proteasomal degradation, but provide a signal for processes like endocytosis, protein 
sorting, membrane trafficking, protein relocalization, ribosomal biogenesis and 
additionally have a large impact within the scope of DNA repair and transcription 
(Galan & Haguenauer-Tsapis, 1997; Hoppe et al., 2000; Hoege et al., 2002; Pickart & 
Fushman, 2004).  
 
 
2.6 Protein activation through regulated partial proteolysis 
 
Regulated nuclear translocation of transcription factors from cytosolic pools is a 
common conduit and a crucial regulatory mechanism by which the cell controls 
transcription. Transcription factors that are kept in a dormant inactive state in the 
cytosol or are anchored to membranes are excellent examples. The signal-induced 
activation of dormant, cytosolic pools of transcription factors seems to be a delicate 
process but guarantees an immediate transcriptional response and must be therefore 
highly specific and tightly regulated. Two fundamentally different mechanisms have 
been identified to activate proteins that are initially synthesized as inactive 
membrane-bound precursors. Both mechanisms include a release from membranes 
by proteolytic cleavage, which then enables the transcription factor to translocate into 
the nucleus and activate transcription of target genes. On the one hand cleavage of 
the precursor can be mediated by site specific proteases by a mechanism termed 
regulated intramembrane proteolysis (RIP) e.g. in Notch or SREBP signaling. On the 
other hand recent studies identified an increasing number of proteasomal substrates 
that are not degraded to completion; only parts of the polypeptide chains are 
eliminated by proteasomal degradation, whereas other parts are spared from 
degradation and released from the proteasome as stable protein fragments. 
Activation of the precursor can occur by a phenomenon coined regulated 
ubiquitin/proteasome-dependent processing (RUP) with the involvement of the 26S 
proteasome (Hoppe et al., 2000; Rape et al., 2001). Examples are maturation of the 
dormant transcription factors Spt23 and Mga2 which are structurally related to NFκB 
and which are essential for the regulation of unsaturated fatty acids in the OLE 
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pathway in S. cerevisiae (Hoppe et al., 2000; Rape et al., 2001; Piwko and Jentsch, 
2006).  
Proteasome mediated processing was described for several substrates 
before: e.g. maturation of the mammalian transcription factor NFκB1 from a dormant 
precursor in the cytosol (Palombella et al., 1994) or proteasome transformation of an 
active full-length transcriptional activator into a fragment that acts as a competitive 
repressor of the active precursor in response to changes in Hedgehog signaling (Ci 
and Gli proteins; Aza-Blanc et al., 1997; Sasaki et al., 1999). The actual mechanism 
for this unconventional activity of the proteasome was largely unknown at this time 
until RUP elegantly explained this non-canonical proteasomal activity (Hoppe et al., 
2000; Rape et al., 2001; Piwko and Jentsch, 2006). Partial proteolysis mediated by 
RUP allows the direct switch of a signaling pathway from one state to another, 
positively or negatively for a cellʼs fate, and thus increases the dynamic range that 
can be achieved through one signaling molecule.  
 
Figure 3. Regulated ubiquitin/proteasome-dependent processing (RUP). (a) Once 
modified by a polyubiquitin chain of at least four ubiquitins (Ub), the substrate can either bind 
directly to intrinsic Ub receptors in the 19S regulatory subunit or to adaptor proteins that 
contain both polyubiquitin- and proteasome-binding domains. (b) Binding of the the substrate 
to the 26S proteasome is followed by protein unfolding by ATPases that encircle the pore of 
the catalytic core, removal and recycling of the Ubiquitins by DUBs (not shown), and 
translocation into the central proteolytic chamber, where it is degraded to completion. (c) 
Emerging studies show a growing number of substrates that are mono/oligoubiquitylated in its 
inactive state and are subsequently processed via the 26S proteasome to an active state with 
different biological function instead of degraded to completion, this phenomenon was coined 
RUP (regulated ubiquitin/proteasome-dependent processing). 
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2.7 The OLE pathway 
 
The regulation of membrane fluidity is of essential importance for the function and 
integrity of the membrane system of the cell. Unsaturated fatty acid levels in yeast 
are largely controlled by an intriguing pathway, coined the OLE pathway (Figure 5b). 
The ER-bound enzyme Δ-9 fatty acid desaturase Ole1 is essential for viability and 
the key enzyme for providing the cell with unsaturated fatty acids. Ole1 catalyzes the 
conversion of saturated to unsaturated fatty acids (UFAs) by introducing double 
bonds into their carbon chains. The balance between saturated and unsaturated fatty 
acids is a crucial parameter that determines membrane fluidity in the cell. 
Disproportionate activation of Ole1, resulting in low levels of unsaturated fatty acids, 
leads to a severe impairment of cellular membrane systems, most notably of the 
nuclear envelope and of mitochondria. In contrast high levels of UFAs are as 
detrimental as low levels for the cell with dramatic consequences for membrane 
composition and pleiotropic defects in the secretory pathways. The Ole1 enzyme 
itself is an integral membrane-bound protein of the ER. Ole1 is a short-lived protein 
and degraded via the ERAD machinery, with its half-life negatively regulated by the 
amount of UFAs resulting in a negative feedback loop (Braun et al., 2002). 
Importantly Ole1 is among the targets of the two transcription factors Spt23 
and Mga2, which are kept initially synthesized as inactive precursors (p120) in the 
cytosol by anchoring to membranes of the ER/nuclear envelope via their C-terminal 
tails. Although deletion of either of the two transcription factors alone seems to have 
no obvious phenotype in yeast, the double deletion is lethal. Interestingly, growth can 
be completely restored by providing the cell with an external source of UFAs (oleic 
acid; Zhang et al., 1999), overexpression of OLE1 itself or by overexpression of a 
truncated variant of the transcription factor Spt23 which resembles a “quasi soluble” 
processed and active form of the precursor (Hoppe et al., 2000; Rape et al., 2001).  
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2.8 Regulated ubiquitin/proteasome-dependent processing 
(RUP): The Spt23 life cycle 
 
Transcription of OLE1 gene is driven by the transcription factor Spt23 (and its 
homolog Mga2), structurally related to the mammalian transcription factor NFκB, and 
activation of the dormant transcription factor is regulated by RUP. The Spt23 life-
cycle is determined by several ubiquitin-dependent events that take place in different 
compartments of the cell and can be subdivided into the maturation of p120 to p90 at 
the ER/cytosol and the inactivation of p90 in the nucleus via polyubiquitylation and 
subsequent 26S dependent degradation (Figure 4a, b; Hoppe et al, 2000; Rape et 
al., 2001).  
Upon fatty acid restriction, homodimerization of the ER membrane-anchored 
Spt23 precursor (p120) takes place and one module of the dimer (p120/p120) is 
mono- or oligoubiquitylated (possibly by a stochastic mechanism) by the essential 
WW-HECT E3 ligase Rsp5. The ubiquitylated module is then subsequently 
processed by the 26S proteasome, both the 19S regulatory subunit and the 20S core 
are needed for processing (Piwko et al., 2006). Previous data elegantly show that the 
Spt23 and Mga2 precursors are endoproteolytically processed by the proteasome 
suggesting that the polypeptide chains of the precursors enter the openings of the 
proteasome as loops, which enables the contact to the active sites located in the 
inner cavity of the proteasome (Piwko et al., 2006). Processing of the dormant p120 
precursor results in the complete degradation of the C-terminal, membrane-anchored 
domain of Spt23 p120, while the N-terminal transcription factor domain (p90) is left 
intact. Interestingly, processing of Spt23 by the proteasome has been shown to occur 
virtually exclusively at the ER membrane. Efficient processing requires dimerization 
via its N-terminus (the Ig-like/plexins/transcriptions, or IPT, domain) and is 
furthermore strictly dependent on the activity of Rsp5. In a second step, the 
processed transcription factor (p90) is liberated from its partner (p120) for nuclear 
targeting by the activity of the chaperone-like complex Cdc48UFD1/NPL4 (Rape et al., 
2001). This enzyme preferentially binds ubiquitylated substrates, and is thereby 
capable of segregating the ubiquitylated, processed molecule from its non-modified 
partner molecule (Rape et al., 2001). After mobilization from the ER membrane the 
liberated p90 migrates to the nucleus and activates OLE1 transcription. 
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Interestingly, the UPS plays again a crucial role in the degradation of p90 in 
the nucleus, most likely after is has initiated OLE1 transcription. Degradation of 
nuclear p90 again involves Cdc48 and additionally Ufd2 and Rad23. Nuclear Spt23 
(p90) in fact still retained its initial monoubiquitin mark and this monoubiquitin can be 
further extended by the chain assembly factor Ufd2, which functions as an E4 
ubiquitin elongation factor (Koegl et al., 1999; Hoppe et al., 2005). Ufd2 also binds to 
Rad23 and thereby enables targeting of polyubiquitylated p90 to the proteasome by 
the ubiquitin escort factor Rad23 (Richly et al., 2005). Interestingly Spt23 p90 is 
partially stabilized in a ufd2 deletion and cells are hypersensitive to the addition of 
UFAs resulting apparently in an unbalanced regulation of OLE1 transcription.  
The mechanism of these specialized activities has been the subject of intense 
investigation (Hoppe et al., 2000; Rape et al., 2001; Piwko and Jentsch, 2006), 
however how these unconventional ubiquitylation events between mono/oligo -and 
polyubiquitylation are regulated is still largely enigmatic especially with regard to the 
differential control of Spt23ʼs fate by the ubiquitin proteasome system. 
 
 
Figure 4. The OLE pathway. (a,b) The Spt23 life-cycle is determined by several ubiquitin-
dependent-events that take place in different compartment of the cell to finally activate Ole1 
transcription in the nucleus: Spt23 p120 monoubiquitylation and  processing at the ER, p90 
mobilization from the ER to the cytosol, p90-mediated transcription in the nucleus, and finally, 
after E4-catalyzed polyubiquitylation of p90, degradation via the 26S proteasome in the 
nucleus. 
Aim 
16 
3 Aim of this study 
 
One of the most extensively studied functions of the 26S proteasome is 
unquestionably the complete degradation of ubiquitylated substrates, but previous 
studies show an increasing number of proteins escaping the canonical pathway of 
complete degradation in favor of proteasomal processing through specialized 
mechanisms. One such mechanism found in our lab was coined “OLE pathway” and 
previous work demonstrated that the synthesis of unsaturated fatty acids in the yeast 
S. cerevisiae is controlled by the essential, WW-domain containing ubiquitin ligase 
Rsp5. The E3 ligase Rsp5, being part of the OLE pathway, targets the NFκB-related 
transcription factor Spt23 (and its close homolog Mga2) for proteasomal processing 
(Hoppe et al., 2000; Rape et al., 2001). However, the regulatory mechanism and 
activation of this non-conventional activity of the proteasome favoring proteasomal 
processing (RUP) over complete substrate degradation remained still largely elusive. 
Therefore the aim of this study was to investigate the underlying regulatory 
mechanism of this unconventional ubiquitylation event: mono/oligo- versus 
polyubiquitylation. The activation of the transcription factor Spt23 in the OLE pathway 
suggests the existence of a regulator for this molecular timing event that tightly 
regulates the ubiquitylation status of Spt23 between the different stages and 
compartments (ER/Cytoplasm, Nucleus). A change in membrane fluidity or 
composition might activate a signaling cascade to induce a conformational change 
into the Spt23 molecule or a binding partner, which thereby could subsequently 
trigger an association of Spt23 with the processing machinery.  
Beyond the initial scope of the study we moreover became interested in what 
determines the specificity whether a substrate is mono/oligo- or polyubiquitylated and 
if there is a unifying regulatory mechanism that might act as a fate switch between 
mono/oligo- and polyubiquitylation. 
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4 Results 
 
4.1 The peptidyl-prolyl cis/trans isomerase Ess1 is an 
essential new player of the OLE pathway  
 
Previously, it was shown that the synthesis of unsaturated fatty acids in the yeast S. 
cerevisiae is tightly controlled by the essential WW domain-containing ubiquitin ligase 
Rsp5 (Figure 5a), which targets the transcription factor Spt23 (Figure 5a; and its 
close homolog Mga2) for proteasomal processing via a non canonical activity of the 
26S proteasome (RUP; Hoppe et al., 2000; Rape et al., 2001; Piwko and Jentsch, 
2006). To investigate additional regulatory components that might be linked to the 
essential OLE pathway, we reviewed earlier studies involving the WW-HECT E3 
ligase Rsp5, which is the crucial E3 ligase in the OLE pathway.  
We indeed observed a genetic link between Rsp5 and the peptidyl-prolyl 
cis/trans isomerase Ess1, the yeast orthologue of Pin1 (Wu et al., 2001).  Both WW 
domain containing proteins act on the same substrate, namely the carboxy-terminal 
domain (CTD) of RNA Pol II (Morris et al., 1999; Chang et al., 2001). The CTD of 
RNA Pol II contains multiple repeats of a proline rich heptapeptide with the 
consensus sequence YSPTSPS (52 repeats in mammalians and 26-27 repeats in the 
yeast S. cerevisiae). Both WW domain containing proteins are essential for viability in 
S. cerevisiae and in both cases substrate specificity is mediated via the WW protein-
interaction domain. RNA Pol II is regulated by CTD phosphorylation (Sudol and 
Hunter, 2000) and while Pin1 was shown to predominantly interact with the 
phosphorylated form of the CTD, Rsp5 was documented to interact preferentially with 
unphosphorylated CTD (Morris et al., 1999; Chang et al., 2000). Interestingly, Ess1 is 
thought to play a positive role in RNA Pol II transcription by generating 
conformational isomers of the CTD, while Rsp5 is thought to play a negative role in 
transcription by mediating RNA Pol II ubiquitylation and degradation via the 26S 
proteasome. The mechanism and the regulation of this mechanism are still largely 
unknown. 
In fact, ubiquitylation of the transcription factor Spt23 (and Mga2) is mediated 
by the WW HECT E3 ligase Rsp5 and recognition and specificity of this interaction is 
mediated via one of the WW domains of Rsp5 (Hoppe et al., 2001), therefore we 
hypothesized that also Ess1 might be linked to the OLE pathway. Opposing effects of 
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Rsp5 and Ess1 on one substrate would be an interesting new regulatory mechanism, 
suggesting a model in which Ess1 and Rsp5 might also act in the OLE pathway.  
Ess1, the yeast orthologue of Pin1, harbors a catalytic (PPIase) domain and 
and a single amino-terminal WW protein interaction domain through which the 
enzyme specifically targets its substrate. Ess1 belongs to the class of Pin1-type 
peptidyl-prolyl cis/trans isomerases, among which Pin1 is special, as its association 
with substrates involves a WW protein-protein-interaction domain that recognizes 
preferentially phosphorylated serine-proline or threonine-proline motifs (pS/TP motifs; 
“proline-directed phosphorylation”; Staub and Rotin, 1996; Sudol, 1996; Yaffe et al., 
1997). Interestingly, the mammalian orthologue Pin functions as a regulatory toggle 
in fate-determining pathways (Lu et al., 2007; Yeh et al., 2007). Pin1 regulates 
diverse cellular processes, including differentiation, cell proliferation, cellular stress 
responses, neuronal function and immune responses. In line with the diverse 
physiological roles of Pin1, it has also been linked to several diseases that include 
tumorigenesis, Parkinsonʼs and Alzheimer's disease. Among the known substrates 
are p53, β-catenin, c-Myc, cyclins, and tau. Furthermore, due to its unique activity to 
switch the conformation of peptidyl-proline bonds, Pin1 and the UPS are often linked, 
but how Pin1 controls protein stability remained largely enigmatic (Wulf et al., 2005; 
Lu et al., 2007). 
 
 
4.1.1 Ess1 is a essential new player in the OLE pathway and functionally 
directly linked to Ole1 
 
To test the hypothesis for a direct physiological role of the peptidyl-prolyl 
cis/trans isomerase Ess1 in the OLE pathway we assayed the otherwise lethal ess1 
deletion (∆ess1) for suppression on oleic acid supplemented plates, which would 
mean a direct implication for Ess1 to act in the OLE pathway. For this purpose yeast 
shuffle-strains were created in which the only source of Ess1 was expressed from the 
endogenous ESS1 promoter from an autonomously replicating centromeric vector 
containing the URA3 marker (∆ess1; ESS1:URA3), as a control, the same strain was 
created for Rsp5 (∆rsp5; RSP5:URA3). In such a setup viability of the strains can be 
tested by plating the transformants on medium containing 5-fluoro-oratic acid (FOA), 
which counterselects for the URA3-encoding plasmid. To test the hypothesis whether 
Ess1 is directly linked to the OLE pathway analogous to Rsp5, transformants were 
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either plated on medium containing FOA or on FOA plates supplemented with 
unsaturated fatty acids (0.2 % oleic acid). Interestingly, we found that the lethality of 
an ess1 deletion strain (∆ess1; Figure 5b, left panel) can be indeed suppressed by 
supplying the cells with unsaturated fatty acids (Figure 5b, right panel). Although 
growth was restored by the addition of oleic acid, ess1 deletion (∆ess1) leads to 
diminutive levels of OLE1 transactivation (compared to ∆rsp5), measured by reporter 
assay (Figure 5d). 
 
 
Figure 5. Ess1 is linked to the OLE pathway.  (a) Schematic diagram of Spt23 showing the 
trans-activation domain (TAD), the NF-κB-like IPT domain, the positions of two ankyrin 
repeats (ANK), and the trans-membrane span (TM). Upon unsaturated fatty acid depletion, 
full-length Spt23 (p120) is ubiquitylated by Rsp5 and subsequently processed (arrow) at the 
ER membrane by the proteasome, yielding the active transcription factor (p90), whereas the 
carboxyl-terminal domain is degraded (dotted line). Schematic diagram of the E3 ligase Rsp5 
and the peptidyl/prolyl isomerase Ess1 showing the double tryptophan (WW) substrate 
interaction motif(s) and the C-terminal catalytic domains, for Rsp5 the HECT E3 ligase 
domain (hect) and for Ess1 the PPiase (PPi) domain, respectively. (b) Growth of the 
otherwise inviable ess1 deletion strain (Δess1) is restored by unsaturated fatty acids (0.2 % 
oleic acid) supplementation (upper panel), or by overexpression of OLE (c) An Ess1 shuffle 
strain (Δess1; ESS1:URA3) was either transformed with empty vector (pADH1-Empty) or with 
a construct constitutively overexpressing Ole1 (pADH1-OLE1), cells were then spotted either 
on FOA plates or FOA plates supplemented with 0.2 % oleic acid. An Rsp5 shuffle strain 
(Δrsp5; RSP5:URA3) strain was used as a control. (d) OLE1 transactivation is dependent on 
Ess1. β-galactosidase expression (ONPG) assays comparing the Ole1 transactivation activity 
of wild-type (WT), rsp5 deletion (∆rsp5) or ess1 deletion (∆ess1) strains bearing an integrated 
pOLE1-LacZ fusion or a mutated pOLE-LacZ as a negative control as indicated. Strains were 
grown in media supplemented with 0.2 % oleic acid (18:1). Graphs represent the mean of 
three independent experiments done in triplicates; standard deviations are indicated. 
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To verify a direct involvement of Ole1 itself we additionally transformed the 
Ess1 shuffle strain (∆ess1; ESS1:URA3) either with empty vector (pADH1-Empty) or 
with a construct constitutively overexpressing Ole1 itself (pADH1-OLE1). Cells were 
then spotted on plates with or without FOA. Notably, overexpression of OLE1 fully 
restored growth of the otherwise lethal ess1 deletion (Figure 5c) demonstrating that 
Ess1 is indeed directly functionally linked to the OLE pathway. 
For further analysis of the role of Ess1 in the OLE pathway a yeast strain was 
created in which the only source of Ess1 was expressed from an autonomously 
replicating centromeric vector containing the URA3 marker (∆ess1; ESS1:URA3). 
This strain was then used to transform constructs encoding Ess1 mutants, viability of 
the Ess1 mutant variants was then tested by plating the transformants on FOA 
containing plates, which counterselects for the URA3 encoding plasmid. 
Consequently, the plasmids encoding Ess1 mutants will remain as the only source of 
Ess1 in the cells plated on FOA containing plates. We tested two temperature-
sensitive (ts) ess1 mutants that were characterized in previous studies (Wu et al., 
2000): One ess1 ts-mutant (ess1-W15R) bears a mutation in the codon of the first 
signature tryptophan (W15R) that results in a ts phenotype at the non permissive 
temperature of 36°C. The other ess1 ts-mutant variant (ess1-H164R) has a single 
amino acid substitution in the catalytic (PPi) domain. The equivalent histidine (H159) 
in Pin1 is characterized to stabilize the covalent intermediate formed with the 
substrate peptide (Wu et al., 2000) and in S. cerevisiae expression of the ess1-
H164R mutant variant leads to a severe ts phenotype already at 34°C (Figure 6a, b).  
The otherwise lethal ess1 deletion strain (∆ess1::HIS) was either transformed 
with ESS1 (WT) or the two Ess1 mutant variants. The resulting strains were then 
either transformed with empty vector (pADH1-Empty; see Figure 6a) or with a 
constitutively overexpressing OLE1 construct (pADH1-OLE1; see Figure 6b). Cells 
were either spotted on plates supplemented with or without 0.2 % oleic acid, and 
finally incubated either at permissive (25°C) or non-permissive temperature (34°C for 
ess1-H164R; 36°C for ess1-W15R). As expected both ess1-ts mutants were either 
rescued by supplementing the cells with unsaturated fatty acids (oleic acid) or by 
overexpression of OLE1 itself when shifted to the otherwise lethal non-permissive 
temperature (Figure 6a, b).  
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Figure 6. Ess1 is a new player in the OLE pathway. (a,b) For further analysis two ess1-ts 
mutants were used in this study (ess1-W15R and ess1-H164R). Growth of the otherwise 
inviable ess1 deletion strain (∆ess1) was either transformed with ESS1 (WT), ess1-W15R or 
ess1-H164R and the strains were cultured at the permissive temperature (25°C). The strains 
were either transformed with empty vector (pADH1-Empty) or with a construct constitutively 
overexpressing Ole1 (pADH1-OLE1), cells were then spotted either on SC plates or SC plates 
supplemented with 0.2% oleic acid and finally shifted to the non-permissive temperature. 
Analogously to Figure 5b,c, growth was restored at the non-permissive temperature by either 
0.2 % oleic acid supplementation (a) or by overexpressing Ole1 itself (b). (c) Suppression of 
ess1-ts mutant (ess1-W15R), colonies of serial diluted ess1-W15R mutant cells that were 
transformed with either empty vector (Empty) or a plasmid isolated as a high-copy suppressor 
of ufd1-2 (spt231-686:URA3; Hoppe et al., 2001; see schematic diagram, right panel) that 
expresses a truncated SPT23 version. The plates were incubated at the temperatures 
indicated on either SC plates or FOA plates to counterselect against the spt231-686:URA3 
plasmid showing that the ess1-W15R strain is inviable withouth the ufd1-1 high-copy 
suppressor after counterselection on FOA. 
 
Previous studies have shown that Spt23 processing results in p90 bound to 
an unprocessed SPT23 p120 partner molecule at the membrane (Hoppe et al., 2000; 
Rape et al., 2001; Piwko et al., 2006). Interestingly, p90 has retained its ubiquitin 
modification after processing, and a chaperone-like enzyme, designated 
Cdc48Ufd1/Npl4, finally separates the p120/p90 heterodimer via an ATP-dependent 
mechanism, thereby mobilizing p90 for nuclear targeting (Rape et al., 2001).  
 Notably, the lethality of the ess1-W15R ts mutant variant at the non-
permissive temperature could also be suppressed by overexpression of a truncated 
clone of Spt23 (Spt231-686:URA3), which was initially genetically linked to the Cdc48 
cofactor Ufd1 (Hoppe et al., 2000). This truncated version of Spt23 operates as a 
“quasi-solube”, processed p90 (Figure 6c, schematic diagram) and is therefore able 
to translocate to the nucleus to drive Ole1 transcription independent of the UPS 
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machinery. Although the rescuing Spt23 variant was overexpressed, these data 
supports a functional relationship between Ess1, Rsp5, Ufd1, Spt23 and Ole1. From 
these findings it can be concluded that the vital function of Ess1 at normal 
temperatures is its role in the essential OLE pathway. 
 
 
4.1.2 Ess1 interacts physically with Spt23 in vivo and in vitro and 
binding is mediated via Ess1ʼs WW domain 
 
The implication of Pin1 as a new player in the OLE pathway and suppression of the 
otherwise lethal ess1 deletion by overexpression of a “quasi-souble” Spt23 p90 
strongly suggested that Spt23 is the target of Ess1 in the OLE pathway.  
 
 
 
Figure 7. Ess1 binds Spt23 in vivo and binding is mediated via the WW substrate 
interaction domain. (a) Ess1 binds Spt23 p120 and p90 in GST pull-down experiments, 
lysates of cells that express myc-tagged Spt23 (pGAL1-10) were subjected to in vitro pull-
down assays with either GST-Ess1 or GST as a control. (b) Two-hybrid interactions of full-
length Rsp5 or Rsp5-WW3 (upper panel), or full-length Ess1 or Ess1-WW, with Spt23 (the 
amino-terminal trans-activation domain and the trans-membrane span were deleted, see 
schematic diagram). Interaction was identified on selective plates (-HIS, +3AT; without 
histidine, plus 3-aminotriazole). Fusions with the Gal4-activation domain (AD) or Gal4-DNA-
binding domain (BD) are indicated (see schematic diagrams of the constructs used). (c) 
Competitive yeast two-hybrid analysis of Spt23, Rsp5 and Ess1. Rsp5 binding to Spt23 (see 
above) was monitored using cells that either contain only the vector (pADH1-Empty), or 
overexpress full-length Ess1 (pADH1-ESS1) from the pADH1 promoter. Interaction was 
identified on selective plates (-ADE; without adenine).  
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Like the WW-HECT E3 ligase Rsp5, Ess1 binds Spt23 (and Mga2) p120 and 
p90 directly as revealed by in vitro GST pull-down assays and two-hybrid analysis 
(Figure 7a, b). Additionally, binding is mediated via the WW interaction domain of 
Ess1 as indicated by two-hybrid analysis (Figure 7b). In fact, Rsp5 and Ess1 partially 
compete for Spt23 binding in two-hybrid assays (Figure 7c), suggesting that WW 
domains of both enzymes may target the same region of Spt23. 
 
 
4.1.3 Ess1 activity is directly linked to Ole1 transactivation via Spt23 
 
When Ess1 was discovered and characterized (Hanes et al., 1989), it was reported 
that not only ess1 deletion is detrimental for viability but also that overexpression of 
Ess1 leads to cytotoxicity (Figure 8a, left panels). Disproportionate levels of Ess1 
might be connected to an imbalance in the transcriptional activation of OLE1. We 
therefore characterized this growth defect in the context of the OLE pathway by either 
overexpressing empty vector (Empty), full-length Ess1 (ESS1) or single domain 
mutants of Ess1, WW domain only (ess1-WW) or the catalytic domain of Ess1 (ess1-
PPi) from the pGAL1-10 promoter. Cells were then spotted in serial dilution on plates 
containing glucose (Figure 8a upper, panels) or galactose (to induce expression from 
the pGAL1-10 promoter) either supplemented with or without 0.2 % oleic acid. Only 
overexpression of full-length Ess1 (ESS1) showed a severe growth defect, while the 
single domains of Ess1 alone (ess1-WW, ess1-PPi) showed no obvious phenotype 
upon overexpression (Figure 8a, left panels). Notably, this growth defect was even 
exacerbated when the cells were in addition spotted on galactose-plates containing 
unsaturated fatty acids (Figure 8a, right panels). Intriguingly, overexpression of ESS1 
directly results in disproportionate up-regulation (> 2.5 fold) of OLE1 transcription as 
measured by reporter assays (Figure 8b). These results confirm that substrate 
recruitment via the WW domain is crucial, and that Ess1 activity is not only directly 
correlated to OLE1 transactivation but OLE transcriptional activation is dependent on 
Ess1. 
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Figure 8. ESS1 activity is directly linked to Ole1 transactivation. (a) Overexpression of 
full-length ESS1 leads to cytotoxicity and hypersensitivity to oleic acid (18:1). Serial dilutions 
of cells expressing ESS1, ess1-WW, or the ess1-PPIase domain (all from pGal1-10 
promoter). Expression by the pGAL1-10 promoter was induced by addition of galactose to the 
medium (lower panels). The plates on the right contain 0.2% oleic acid. (b) ESS1 activity is 
directly correlated with Ole1 transactivation. β-galactosidase expression (ONPG) assays with 
wild-type strain bearing an integrated pOLE1-LacZ fusion or a mutated pOLE-LacZ as a 
negative control as indicated, overexpressing either vector (Empty), ESS1, ess1-WW, or 
ess1-PPi under the pGAL1-10 promoter. Graphs represent the mean of three independent 
experiments done in triplicates; standard deviations are indicated; β-galactosidase activity 
was normalized to the (Empty) control (set to 100%). (c) β-galactosidase expression (ONPG) 
assays comparing the Ole1 transactivation activity of wild-type (WT), spt23 deletion (∆spt23) 
or mga2 deletion (∆mga2) strains bearing an integrated pOLE1-LacZ fusion or a mutated 
pOLE-LacZ as a negative control as indicated. (d) Cytotoxicity due to ESS1 overexpression is 
suppressed in a spt23 deletion strain (∆spt23) but not ∆mga2. Serial dilutions of cells either 
expressing ESS1 or RSP5 (both from pGAL1-10 promoter) in different deletion backgrounds 
comparing WT, ∆spt23 and ∆mga2. Expression was induced by addition of galactose to the 
medium (right panels). 
 
OLE1 transactivation is regulated via the two transcription factors Spt23 and 
Mga2, being functionally overlapping. Indeed, the ∆spt23 ∆mga2 double deletion is 
lethal, while the ∆spt23 or ∆mga2 single deletions show no obvious phenotypes and 
are viable (Zhang et al., 1997). Either one of the transcription factors is enough to 
ensure viability but to what extent they contribute to OLE1 transcription is still elusive. 
In order to analyze the contribution of Spt23 and Mga2 to the OLE pathway we 
measured the OLE1 transactivation by reporter assays in either wild-type (WT), spt23 
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deletion (∆spt23) or mga2 (∆mga2) deletion backgrounds. Interestingly, OLE1 
activation was strikingly reduced in ∆spt23 compared to ∆mga2 (Figure 8c), although 
Ess1 seems to bind Spt23 and Mga2 in GST pull-down assays to the same extent 
(Figure 7a). Furthermore, toxicity due to ESS1 overexpression was surprisingly 
suppressed in a ∆spt23 while there was no suppression observed in wild-type (WT) 
or ∆mga2 (Figure 8d, upper panels). In contrast to this directed contribution of ESS1 
activity towards Spt23, RSP5 seems to contribute to both transcription factors to the 
same extent (Figure 8d, lower panels). These results indicate that Ess1 is 
functionally directly linked to OLE1 transcriptional activation mainly via the 
transcription factor Spt23. We therefore conclude that Ess1 is an essential new 
player in the OLE pathway.  
 
 
4.2 Ess1 interacts with Spt23 in a phosphorylation-dependent 
manner in vivo and in vitro 
 
The reversible phosphorylation of proteins on certain serine or threonine residues 
that immediately precede a proline (pS/T-P) appears to be an important regulatory 
switch for several cellular processes such as cell proliferation and differentiation 
(Blume-Jensen et al., 2001; Lu et al., 2002). The significance of phosphorylation 
dependent conformational changes becomes clear with the discovery of the unique 
peptidyl-prolyl cis/trans isomerase Pin1 in 1995 (Lu et al.), which specifically 
isomerizes phosphorylated S/T-Pro motifs and is a prerequisite for Pin1 substrate 
recognition and PPiase activity.  
 
 
4.2.1 Spt23 phosphorylation is a prerequisite for Ess1 binding and 
activity 
 
To uncover whether Spt23 contains a phosphorylated S/T-Pro motif, we examined 
phosphorylation of Spt23 in vivo. Indeed, by using the monoclonal antibody MPM2, 
which specifically recognizes phosphorylated S/T-Pro motifs (Lu et al., 1999) we 
observed reactivity for both Spt23 p120 and p90 forms (Figure 9a, middle panel, left 
lane). MPM-2 reactivity was significantly reduced by treatment with λ-phosphatase 
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(Figure 9a, middle panel, right lane) and phosphatase treatment also abolished in 
vivo binding of Ess1 to Spt23 (Figure 9a, lower panel). Furthermore, in in vitro GST 
pull-down assays Ess1 binds to Spt23 in a phosphorylation-stimulated manner, and 
binding is lost when the samples were treated with λ-phosphatase (Figure 9b). These 
results demonstrate that Spt23 is in fact modified by proline-directed phosphorylation 
and that phosphorylation is indeed a prerequisite for effective Ess1 binding to Spt23.  
 
 
Figure 9. Spt23 is modified by proline-directed phosphorylation and Ess1 binding is 
stimulated by phosphorylation. (a) Spt23 is modified by proline-directed phosphorylation in 
vivo and a prerequisite for Ess1 binding. Lysates of cells that express myc-tagged Spt23 
(pGAL1-10 promoter) and HA-tagged Ess1 were incubated with or without λ-phosphatase, 
followed by myc-immunoprecipitation (IP) and immunoblotting using an anti-myc antibody 
(upper panel), a mitotic phosphoprotein monoclonal 2 (MPM2, Upstate) antibody, which is 
specific for phopho-Ser/Thr-Pro sites (middle panel), or an HA-epitope specific antibody 
(lower panel). Treatment with λ-phosphatase abolishes binding of Ess1 (Ess1-HA) to Spt23. 
(b) Ess1 binds to Spt23 in a phosphorylation-stimulated manner in in vitro GST-pull-down 
experiments as indicated by treatment with or without λ-phosphatase. (c) Schematic diagram 
of Spt23 showing Ess1 binding to a central region of Spt23 (aa624-774) determined by two-
hybrid analysis (data not shown and Figure 5a), which contains a Ser-Pro site (SP) in the p90 
part of p120. Spt23 variants with serine-to-alanine (S-A) alterations in the Ess1-binding site as 
the only source for Spt23 are defective in Ess1 binding as indicated by pull-down experiments 
using GST-tagged Ess1. mycSpt23HA WT or variants (expressed from endogenous promoter) 
were transformed to a spt23 deletions strain (∆spt23) and used in in vitro pull-down 
experiments. 
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Mapping experiments by two-hybrid assays with various Spt23 truncations and 
Ess1 revealed a central region of Spt23 (aa 624-774) as the major binding site for 
Ess1 (data not shown and Figure 9c, upper schematic diagram). Interestingly, this 
site is not only implicated in the processing of Spt23 p120 and close to the presumed 
ubiquitylation site, but also the predicted site for loop formation and proteasome entry 
(Piwko et al., 2006). We further noticed that the identified Ess1-binding region in 
Spt23 contains a typical Ser-Pro motif (SP654,655) surrounded by several additional 
serines (aa 651-656), which is interestingly located in the p90 part of Spt23. To 
further characterize the Ess1 binding to Spt23 we conducted in vitro GST pull-down 
assays with Spt23 versions where serine and proline residues in the identified core 
binding region (aa 651-656) were changed to alanine. Changing the respective serine 
and proline to alanine (SP654,655AA) abolished Ess1 binding, also changing all 4 
serines to alanine (SSSS651,653,654,656AAAA) reduced binding to Ess1 significantly 
(Figure 9c, lower panels). Changing only one serine to alanine (S651A) showed a 
milder reduction in binding to Ess1, most likely due to the fact that another serine 
nearby is used (“phosphorylation-site hopping”). 
The WW protein interaction domain of Pin1-type PPIases functions as a pS/T-
Pro binding module. The pS/T-Pro binding pocket within the WW domain is highly 
conserved and involves several critical residues, including Tyr23, Trp15, Ser16 and 
Arg17. Tyr23 was previously characterized to be crucial for mammalian Pin1 to 
recognize phosphorylated substrates (Lu et al., 1999). 
To further address the functional relevance of the phosphorylation-dependent 
binding of Ess1 to Spt23 we performed in vitro GST pull-down assays. Intriguingly, 
changing a conserved tyrosine residue (Y23A) of GST-tagged Ess1 (Figure 10a, WW 
domain alignment), which lies in the phospho-recognition binding pocket of the WW 
domain of Ess1, abolishes the Ess1-Spt23 binding almost completely (Figure 10a). 
These results strongly support the conclusion that Ess1 binding to Spt23 is mediated 
via Ess1ʼs WW domain and demonstrates that Spt23 is recognized by the yeast 
PPiase similar to most other Pin1 substrates in a phosphorylation dependent manner 
(Lu et al., 2007). 
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Figure 10. Ess1 WW Tyr23 is essential for recognition of Spt23, activity and viability. 
(a) Ess1 binds Spt23 p120 and predominantly p90 in GST pull-down experiments, but a 
variant with an alteration in the WW domain essential for phospho-dependent substrate 
recognition (GST-Ess1Y23A; see schematic diagram above) is defective in Spt23 binding. (b) 
An Ess1 variant with an alteration in the WW domain (ess1-Y23A) unable to bind Spt23 is not 
able to restore growth of the otherwise inviable ess1 deletion strain (ess1Δ; contructed as in 
Figure 5b). Overexpression of this variant in wild-type cells causes no cytotoxity (c) serial 
dilutions of cells overexpressing (pGAL1-10 promoter) either empty plasmid (Empty), Ess1, or 
a variant of Ess1 with an alteration in the WW domain (Ess1-Y23A) that is defective in Spt23 
binding. Expression was induced by addition of galactose to the plates (right panel). 
 
Genetic support for this conclusion is derived from the finding that cells 
expressing this mutant variant (ess1-Y23A) as the only source of Ess1 are not viable 
(Figure 10b). Furthermore overexpression of WT Ess1 is toxic, but not of the mutant 
(Y23A) (Figure 10c), both results demonstrate the biological relevance of phospho-
recognition mediated via Ess1ʼs WW domain.  
 
 
4.2.2 Spt23 interacts with CK2, is phosphorylated by CK2 in vivo and in 
vitro and promotes binding to Ess1 
 
To identify the responsible kinase for Spt23 regulation we perfomed a two-hybrid 
screen (data not shown) and identified all four subunits of casein kinase 2 (CK2; 
Cka1, Cka2, Ckb1, Ckb2) as strong interactors of Spt23 which we confirmed by 
immunoprecipitation assays with mycSpt23HA (expressed from the pGAL1-10 
promoter) with GFP-fusions of all four CK2 subunits (Figure 11a), control 
experiments were carried out in parallel using cells that do not express mycSpt23HA 
(otherwise identical) showing no precipitation after immunoblotting using a GFP-
specific antibody (Figure 11b). 
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Figure 11. Spt23 binds to 
all four subunits of 
Casein Kinase 2 (CK2) in 
vivo. (a) Spt23 co-
immunoprecipitates with all 
CK2 subunits. Lysates of 
cells expressing mycSpt23HA 
under the control of the 
pGAL1-10 promoter and 
GFP-tagged CK2 subunits 
(Cka1, Cka2, Ckb1, Ckb2), 
GFP-tagged Fcp1 as a 
negative control, or an 
untagged strain were 
subjected to myc-
immunoprecipitation (IP) 
and immunoblotting using a 
GFP-specific antibody 
(upper panel), or an anti-
myc antibody (middle 
panel). The lower panel 
shows the input identified 
by an anti-GFP immunoblot. 
(b) Control experiment were 
carried out (right panel) 
using cells that do not 
express mycSpt23HA (otherwise identical). Immunoprecipitation using anti-myc antibodies does 
not precipitate CK2 in this control experiment.  
 
Pin1 was shown to bind to pS-Pro motifs in the C-terminal domain of the large 
subunit of RNA polymerase II (CTD) and was discussed to stimulate CTD 
dephosphorylation by its phosphatase Fcp1 in the nucleus (Kops et al., 2002). We 
therefore included Fcp1 as a potential Spt23 phosphatase in our pull-down 
experiments, but GFP-tagged Fcp1 does not interact with Spt23 (Figure 11a) and 
therefore served as a negative control.  
Furthermore, we speculated that binding of Ess1 to Spt23 might be stimulated 
by the protein kinase CK2. Treating cells with the specific CK2 inhibitor 4,5,6,7-
tetrabromo-benzotriazole (TBB) showed that binding of Ess1 to Spt23 was indeed 
significantly reduced as indicated in GST pull-down experiments (Figure 12a) 
In addition, isolated Spt23 forms can be phosphorylated  with recombinant CK2 
in vitro (Figure 12b). Samples were first dephosphorylated by λ-phosphatase due to 
residual in vivo phosphorylation of mycSpt23HA immunopurified from cells, followed by 
an in vitro phosphorylation reaction with recombinant CK2 and 32PγATP. Indeed, 
samples pre-dephosphorylated showed stronger sensitivity in the autoradiograph 
compared to samples that were not dephosphorylated before CK2-phosphorylation 
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(Figure 12b, right panel, compare left and right lane), while cells that do not express 
mycSpt23HA showed no reactivity (Figure 12b, left panel).. 
 
 
Figure 12. Ess1 binding to Spt23 is stimulated by phosphorylation mediated by Casein 
Kinase 2 (CK2). (a) Ess1 binding to Spt23 is lost when cells were treated with the CK2 
inhibitor TBB, as indicated by GST pull-down experiments. (b) Isolated Spt23 forms can be 
phosphorylated in vitro by recombinant CK2. Cells not expressing (left panel) or 
overexpressing mycSpt23HA (pGal1-10 promoter; right panel) were subjected to myc-
immunoprecipitation, due to in vivo phosphorylation samples were then incubated with or 
without λ-phosphatase followed by in vitro phosphorylation with recombinant CK2 and 32P-γ-
ATP.  
 
Remarkably, immunopurified Spt23 forms interact with recombinant GST-
tagged Ess1 in a CK2 phosphorylation-stimulated manner in vitro. Immunopurified 
mycSpt23HA was first treated with (or without; as a negative control) λ-phosphatase to 
remove in vivo phosphorylation. After phosphatase treatment samples were left 
untreated or in vitro phosphorylated with recombinant CK2 (as above, but with non-
radioactive labeled ATP). These samples were finally incubated with recombinant 
GST-tagged Ess1 or GST alone (as a negative control). The supernatant of the last 
step was then used in GST pull-down assays (with GST-Sepharose) to measure the 
amount of free unbound GST-Ess1 to Spt23-bound GST-Ess1 (Figure 13a, middle 
panel, compare left and right panels): Recombinant Ess1 was only co-
immunopurified by CK2-phosphorylated Spt23, see quantification for the amount of 
Ess1 bound to Spt23 (Figure 13a, middle left panel) compared to Ess1 unbound to 
Spt23 (Figure 13a, middle right panel). By using an antibody specific for the β-subunit 
of CK2 we observed, that CK2 was only efficiently bound when the samples were 
pre-dephosphorylated (Figure 13a, lower panel).  
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Figure 13. Spt23 interacts with Ess1 in a CK2 phosphorylation-stimulated manner in 
vitro. (a) Extracts of cells expressing mycSpt23HA under the control of the pGAL1-10 promoter 
were subjected to immunoprecipitation using anti-myc antibodies and incubated with or 
without λ-phosphatase. After phosphatase treatment, the washed samples were left untreated 
or phosphorylated in vitro with recombinant CK2. These samples were finally incubated wirt 
either recombinant GST-Ess1 or GST alone (control). The unbound GST-Ess1 material 
(supernatant of the last experiment) was subjected to a GST pull-down with GST-Sepharose 
to compare the amount of free to Spt23-bound GST-Ess1 material. The upper panel shows 
the anti-myc immunoblot of immunoprecipitated mycSpt23HA treated with or without λ-
phosphatase. The central left panel shows an anti-GST immunoblot of GST-Ess1 that co-
immunoprecipitated with mycSpt23HA (GST-Ess1 bound to Spt23) when phosphorylated by 
CK2. The central right panel shows unbound GST-Ess1 pulled down by GST-Sepharose from 
the supernatant. The lower panel shows an immunoblot using antibodies directed against the 
CK2β-subunit of CK2, showing that CK2 binds anti-myc immunoprecipitated, in vitro 
phosphorylated mycSpt23HA. 
 
 
4.2.3 Phosphorylation of Ess1 on Ser16 seems to be negatively 
correlated with its activity and localization 
 
Evidence suggests that PPiase activity itself is subject to physiological regulation (Lu 
et al., 2002). As shown before (Figure 10a-c) the WW protein interaction domain of 
Pin1-type PPIases functions as a pS/T-Pro binding module, interestingly Ser16 is 
located in the center of pS/T-Pro binding pocket. In a recent study it was 
demonstrated that mammalian Pin1 is modified by phosphorylation in the WW 
domain at Ser16. Interestingly, this phosphorylation site seems to regulate nuclear 
localization of Pin1 and substrate binding (Lu et al., 2002).  
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To examine the biological relevance of Ser16 phosphorylation of S. cerevisiae 
Pin1, we used an Ess1 shuffle-strain (∆ess1; ESS1:URA3) in which the only source 
of Ess1 was expressed from the endogenous ESS1 promoter from an autonomously 
replicating centromeric vector containing the URA3 marker. This shuffle-strain was 
then either transformed with plasmids expressing WT Ess1 (ESS1) or Ess1 variants 
in which Ser16 was replaced by alanine (S16A) or glutamic acid (S16E) by site-
directed mutagenesis (Figure 14a). These strains were assayed for survival after 
counterselection of the URA3 plasmid (ESS1:URA3) on FOA plates. Consequently, 
the plasmids encoding Ess1 mutants will remain as the only source of Ess1 in these 
cells. Interestingly, a Ess1 phospho-deficient Ser16 variant (ess1-S16A) is able to 
rescue the otherwise lethal ess1 deletion (after counterselection on FOA plates). By 
contrast, a Ess1 phospho-mimicking variant (ess1-S16E) failed to suppress the 
∆ess1 lethality (Figure 14b). Genetic support for the biological relevance of Ess1 
Ser16 was obtained by the observation that overexpression of the phospho-
mimicking Ser16 mutant (ess1-S16E) shows no growth defect when spotted on 
galactose containing plates, while the phospho-deficient Ser16 variant (ess1-S16A) 
shows the same toxic phenotype as overexpression of WT Ess1 (ESS1) (Figure 
14c). These results indicate that not only the Tyr23 phospho-recognition site is 
crucial (Figure 10a-c), but also Ser16 seems to be crucial for Ess1 functioning 
properly. 
 
 
Figure 14. Ess1 Ser 16 phosphorylation is essential for Ess1 activity andviability. (a) 
Schematic diagram showing the Ess1 phospho-deficient Ser16 variant (ess1-S16A) and the 
phospho-mimicking Ser16 variant (ess1-S16E) (b) A phospho-mimicking Ser16 mutant (ess1-
S16E) is not able to restore growth of the otherwise inviable ess1 deletion strain (ess1Δ; 
contructed as in Figure 5b) while a phospho-deficient (ess1-S16A) variant is viable in 
comparison to wild-type Ess1. (c) Overexpression (pGAL1-10 promoter) of the phospho-
deficient Ser16 variant (S16A; lower right panel) in wild-type cells is toxic while the phospho-
mimicking Ser16 variant (S16E; upper right panel) is unaffected.  
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Remarkably, the genetic data correlates with localization studies perfomed with 
GFP-tagged Ess1 and the Ser16 mutant variants of Ess1 (expressed from the 
pMET25 promoter). Ess1 localization might be driven by substrate interaction via the 
WW domain as it was postulated for mammalian Pin1 (Lu et al., 2002). Although GFP 
was localized in both nucleus and cytoplasma, GFP-Ess1 was predominantly 
localized to the nuclear compartment and the ER (Figure 15a). Notably, a GFP-WW 
domain exhibited the same pattern as GFP-Ess1, whereas the GFP-PPIase domain 
was observed as a diffuse pattern in the whole cell (data not shown).  
 
 
 
Figure 15. Ess1 Serine 16 phosphorylation regulates subcellular localization. (a) 
Intracellular localization of GFP-tagged Ess1 wild-type (WT) and Ess1 Ser16 variant ess1-
S16A and ess1-S16E expressed from the pMET25 promoter were investigated by confocal 
microscopy. Representative fluorescent images (upper panels) and transmitted light images 
(lower panel) are shown. (b) Ess1 binds Tpk1 and Tpk2 in GST pull-down experiments, 
lysates of cells that express chromosomally ProA-tagged Tpk1 and Tpk2 were subjected to in 
vitro pull-down assays with either GST-Ess1 or GST as a control. 
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These data corroborates the fact that the WW domain determines substrate 
specificity and thereby the subcellular loalization of Ess1, consistent with recent 
reports for Pin1 (Lu et al., 2002; Rippmann et al., 2000). We then further analyzed 
whether Ess1 localization can be regulated by phosphorylation of Ser16. The 
phospho-deficient Ser16 (GFP-ess1-S16A) mutant variant is still localized 
predominantly to the nuclear compartment as wild-type Ess1 (GFP-ESS1). By 
contrast, the phospho-mimicking mutant (GFP-ess1-S16E) was distributed diffusely 
in the cell resembling a Ess1 version lacking the WW domain (Figure 15a, two panels 
to the right). These results demonstrate that the Ess1 phospho-mimicking (S16E) 
variant is not only non-functional (Figure 14b, c) but also the normal subcellular 
localization of Ess1 is disrupted.  
Previously, it was reported (Lu et al., 2002) that Pin1 Ser16 phosphorylation 
might be regulated via cAMP (cyclic AMP)-dependent protein kinase A (PKA) in vitro. 
PKA treatment resulted in dissociation of Pin1 from MPM2 antigens, suggesting that 
the phosphorylation might actively disrupt the interaction between Pin1 and a 
substrate (Lu et al., 2002). In vitro pull-down assays with recombinant GST-Ess1 and 
the yeast PKA orthologues Tpk1 and Tpk2 indeed show binding of Ess1 to the PKA 
orthologues (Figure 15b).  
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4.3 Pin1 controls the degree of substrate ubiquitylation and 
thereby determines substrates fate 
 
Regulation of protein activity often involves signaling through post-translational 
modifications, these either induce a structural change in the protein, thereby altering 
its activity, or induces the exposure of sites recognized by regulatory proteins. Pin1 
induced conformational changes have profound effects on the function of many 
substrates (Lu et al., 2002; Lu et al., 2007). Intriguingly, Pin1 was in some cases 
reported to correlate with a change in substrate stability linked to the UPS (Liao et al., 
2009; Lu et al., 2007; Zheng et al., 2002; Zacchi et al., 2002). Therefore it was 
tempting to speculate that Pin1 might regulate Spt23 stability by a S/T-Pro-directed 
post-phosphorylational cis/trans isomerization. 
 
 
4.3.1 Ess1 determines the fate of Spt23 by a cis/trans isomerization 
 
To test whether a Pin1-mediated cis/trans isomerization of Spt23 leads to a change 
in Spt23 stability we followed the steady-state levels of Spt23 over time in two 
different temperature-sensitive (ts) mutants expressing Ess1 variants: one with 
alteration in the WW domain (ess1-W15R), the other with an amino acid substitution 
in the catalytic (ess1-H164R) domain. Indeed, we found that the steady-state level of 
Spt23 was drastically reduced over time in two different temperature-sensitive (ts) 
mutants expressing Ess1 variants after the cells were shifted to the non-permissive 
temperature (Figure 16a).  
When we further characterized Spt23 processing in detail in an expression 
shut-off experiment, we observed a rapid decay of Spt23 levels in the ess1 mutants 
compared to WT cells at the restrictive temperature (Figure 16b). Notably, p90, the 
active transcription factor, rapidly disappeared to diminutive levels over time, 
because the p120 precursor was quickly turned over by degradation (Figure 16b). 
The quantification (Figure 16c) further reveals the drastic differences in the 
life-span of Spt23 p120 in the ess1 mutants compared to WT (ESS1): In WT cells 
Spt23 p120 is efficiently processed to the active transcription factor p90, indicated by 
increasing p90 and decreasing p120 levels over time. By contrast, in the ess1 
mutants p120 as well as p90 levels decreased rapidly over time.  
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Figure 16. Ess1 determines Spt23 fate by a cis/trans isomerization. (a) Steady state 
levels of mycSpt23HA expressed in WT, ess1-W15R, and ess1-H164R mutant cells. Samples 
were taken (0-120 min) after shifting to the non-permissive temperature (37°C) of the ts-
mutants and analyzed by anti-myc immunoblots (upper panel). Dpm1 was used as a loading 
control (lower panel). (b) Spt23 p120 is short lived in ess1 mutants. Expression shut-off 
experiments with WT, ess1-w15r, and ess1-h164r mutant cells expressing mycSpt23HA by the 
pGAL1-10 promoter. Cells were grown in a galactose-containing medium to an OD600 of 0.4 at 
23°C and shifted for another 2 h to 37°C. After adding glucose and cycloheximide (to block 
translation) to the medium, samples were taken at the indicated time points, and Spt23 levels 
were analyzed by anti-myc immunoblots (upper panel). Dpm1 was used as loading control 
(lower panel). The graph (c) shows the quantification of the respective protein levels (100% 
was defined as p120 levels at time point 0). (d) Ess1 regulates OLE1 transcription via Spt23. 
ESS1 (WT), ess1-W15R, and ess1-H164R cells expressing β-galactosidase by the OLE1-
promoter (pOLE1-LacZ) were grown either at 23°C (dark grey) or for 2 h at 37°C (light grey). 
Samples were withdrawn and β-galactosidase activity was measured by an ONPG (ortho-
nitrophenyl-β-galactoside) assay. Graphs represent the mean of three independent 
experiments done in triplicates. Standard deviations are indicated. A mutated pOLE1 
promoter is inactive in this assay (right graph). 
 
The reduction in p90 levels in the two ess1 mutants, especially in the catalytic ts-
mutant ess1-H164R, nicely correlated with their capacity to drive OLE1 transcription 
in cells, as measured by reporter assays (Figure 16d). 
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Figure 17. Spt23 variants with alterations in the Ess1 binding site are short lived. (a) 
Spt23 p120 is short lived when either serine (S-A), proline (P-A) or both residues (SP-AA) are 
mutated to alanine in the Ess1 binding site of Spt23. Expression shut-off experiments with 
mycSpt23HA WT or Spt23 variants with serine-to-alanine (S-A) or proline-to-alanine (P-A) 
alterations expressing mycSpt23HA under its endogenous promoter in a ∆spt23 deletion strain. 
Cells were grown to an OD600 of 0.8 in selective medium, after adding cycloheximide (to block 
translation) to the medium, samples were taken at the indicated time points, and Spt23 p120 
levels were analyzed by anti-HA immunoblots (upper panel). Dpm1 was used as loading 
control (lower panel). The graph (b) shows the quantification of the respective protein levels 
(100% was defined as p120 levels at time point 0). (c) Spt23 variants with serine-to-alanine 
(S-A) or proline-to-alanine (P-A) alterations in the Ess1 binding site are unable to complement 
the otherwise inviable ∆spt23 ∆mga2 deletion strain. 
 
Interestingly, re-examining the Spt23 variants with mutations in the Ess1-
binding site for p120 (Figure 9c, d) in fact revealed that Spt23 is short lived in these 
mutants (Figure 17 a,b). Changing the respective serine and proline to alanine 
(SP654,655AA) drastically reduced p120 levels. Also changing all 4 serines to 
alanine (SSSS651,653,654,656AAAA) reduced Spt23 p120 half-life significantly. 
Changing only one serine to alanine (S651A) showed a milder reduction in p120 
levels, again in line with the binding assays (Figure 9c, d) most likely due to 
“phosphorylation-site hopping” (Figure 17a, b). Notably, these residues are indeed 
crucial for Spt23 activity as strains expressing these mutant proteins as the only 
source of Spt23 are not viable (Figure 17c). The explanation is most likely because of 
the fact that the encoded proteins are short-lived as shown above (Figure 17a, b) in 
expression shut-off experiments. 
These results suggest that the ∆ess1 null mutant is inviable because the 
Spt23 transcription factor precursor is completely degraded instead of being 
processed in these cells. 
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4.3.2 Pin1 acts as a binary fate switch by controlling Spt23 ubiquitylation 
 
The activity of the peptidyl-prolyl isomerase Pin1 directly influences the stability of 
Spt23 and therefore the fate of the transcription factor. Hence, the question was 
whether Ess1 acts by controlling the ubiquitylation status of Spt23 and furthermore, if 
Ess1 might act as a binary fate switch by inducing a cis/trans conformational change 
in the polypeptide chain that is translated into a change in substrate ubiquitylation 
and thereby substrate fate. 
To directly test the influence of Ess1 on Spt23 ubiquitylation, we compared 
the Spt23 ubiquitylation patterns of WT  and ess1-ts mutants (ess1-W15R). Cells that 
express mycSpt23HA (from the pGAL1-10 promoter) and His-tagged ubiquitin (from the 
pMET25 promoter) were shifted for 3 hours to the non-permissive temperature (37°C) 
of the ess1 mutant and ubiquitin conjugates were isolated by denaturing Ni-NTA pull-
down. Whereas Spt23 ubiquitylation occurs only at low levels on both p120 and p90 
forms in WT cells (Hoppe et al., 2000; Rape et al., 2001), Spt23 p120 ubiquitylation 
was dramatically induced in the ess1-W15R mutant after shifting to the non-
permissive temperature. This drastic induction in ubiquitylation was accompanied by 
rapid Spt23 decay (Figure19a, see also quantification below).  
To address the involvement of the proteasome directly, we followed Spt23 
p120 ubiquitylation in the ess1-W15R mutant in a time course experiment with or 
without the proteasome inhibitor MG132. After an initial shift of 2 hours to the non-
permissive temperature (Figure 18b, lane 2 from left) cells were either treated with 
(Figure 18b, lane 6-8) or without MG132 (Figure 18b, lane 3-5) and ubiquitin 
conjugates were isolated by denaturing Ni-NTA pull-down. As observed before 
(Figure 18a) Spt23 p120 ubiquitylation is strongly induced in the ess1-ts mutant after 
2 hours. Notably, Spt23 ubiquitylation stays high over time when the cells were 
treated with the proteasomal inhibitor MG132 (Figure 18b, lane 6-8), while the p120 
ubiquitylation decreased over time in samples untreated for MG132, indicative of 
ongoing degradation of p120 in the ess1-ts mutant. 
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Figure 18. Ess1 controls the degree of substrate ubiquitylation. (a) Ubiquitylation of HA-
tagged Spt23 protein (p120) of WT and the ess1-W15R mutant. Cells expressing mycSPT23HA 
(glucose-repressible pGAL1-10 promoter) and HIS-tagged ubiquitin (HISUb; pMET25 
promoter) were grown to an OD600 of 0.4 at 23°C (Input 23°C) and shifted (arrow) to 37°C and 
grown for another 3h (Input 37°C). Thereafter, HISUb-modified proteins were isolated under 
denaturing conditions by Ni-NTA pull-down. Inputs and precipitates were probed with HA-
specific antibodies (upper panels). To normalize pull-down efficiency, cells (10 OD600) 
expressing HIS-tagged Pol30 were added to the samples before harvesting, and the blots 
were re-probed with an antibody against Pol30 (lower panel). Polyubiquitylated Spt23 p120 is 
indicated, the quantification below refers to the level of polyubiquitylated Spt23 p120. (b) 
Ubiquitylation time course of HA-tagged Spt23 protein (p120) from ess1-w15r (∆pdr5 
background) after addition of the proteasomal inhibitor MG132. Cells expressing mycSPT23HA 
(pGal1-10 promoter) and HIS-tagged ubiquitin (HISUb; pADH1 promoter) were grown to an 
OD600 of 0.4 at permissive temperature (25°C) and then preshifted to the permissive 
temperature (37°C) for 2h. Cell were then treated with or without proteasomal inhibitor 
MG132, samples were withdrawn at the indicated time points and subjected to HISUb pull-
down assays under denaturing conditions (Identification of proteins as in Figure 18a). The 
quantification below refers to the level of polyubiquitylated Spt23 p120. Note that polyubiquitin 
levels of p120 are unstable most likely due to ongoing proteasomal degradation, while the 
p120 poyubiquitin levels are stable in cells treated with MG132.  
 
We further addressed the question, whether this striking boost of Spt23 
precursor ubiquitylation is directly regulated by Ess1 activity by gradually reducing 
Ess1 levels in cells and following p120 ubiquitylation. Therefore a ∆ess1 strain was 
constructed that is rescued by a galactose-inducible Ess1 (∆ess1; pGAL1-10-ESS1), 
additionally expressing His-tagged ubiquitin (from the pADH1 promoter). This strains 
was cultivated on selective plates at low galactose/raffinose (0.5% / 1.5%) levels for 
cell survival. This experimental setup bears the advantage that it does on rely on a 
temperature shift, to reduce Ess1 levels we simply change the type of carbon-source 
from galactose to glucose. Cells were then shifted to high glucose/raffinose medium.  
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We followed Spt23 p120 precursor ubiquitylation in a glucose shut-off experiment 
where the expression of Ess1 is gradually reduced by turning off its expression after 
addition of glucose to the cells. Ubiquitin conjugates were then isolated by denaturing 
Ni-NTA pull-down. Remarkably, after shutting off Ess1 expression, ubiquitylation of 
Spt23 occurs rapidly and steadily in cells: low levels of p120 ubiquitylation at the 
beginning with high levels of Ess1 followed by massive polyubiquitylation of p120 
over time with low levels of Ess1. These data indicate that the degree of Spt23 p120 
ubiquitylation is reversely correlated with Ess1 activity in cells (Figure 19a, b), Ess1 
crucially controls the balance between Spt23 processing versus complete 
degradation through regulating substrate ubiquitylation. 
 
 
 
 
 
Figure 19. The degree Spt23 p120 ubiquitylation is correlated with Ess1 activity. (a) 
Lowering Ess1 levels results in enhanced Spt23 ubiquitylation. Null mutant of ESS1 (Δess1) 
complemented by a construct that expresses ESS1 from the GAL1-10 promoter (pGAL-ESS1) 
were pregrown to an OD600 of 0.5 at 30°C in a 1.5 % raffinose, 0.5 % galactose-containing 
medium to express ESS1. To turn off ESS1 expression, cells were then shifted to a 2% 
glucose-containing medium and samples were withdrawn at the indicated time points. 
(Identification of proteins as in Figure 13a). The quantification below refers to the level of 
polyubiquitylated p120 Spt23. (b) Control experiment for Figure 19a. To exclude a side-effect 
of the nutritional downshift from a galactose to a glucose-containing medium, a wild-type 
strain expressing HIS-tagged ubiquitin and mycSpt23HA was grown to an OD600 of 0.5 at 30°C 
in a 1.5 % raffinose, 0.5 % galactose containing medium, the cells were then shifted either to 
a 2 % galactose or 2 % glucose-containing medium, and samples were withdrawn and 
subjected to isolation of ubiquitylated proteins as in Figure 18a. The quantification below 
refers to the level of polyubiquitylated p120 Spt23. Note that this media shift does not induce 
Spt23 ubiquitylation. 
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4.4 Pin1 acts as a fate switch by controlling p53 ubiquitylation 
 
The peptidyl-prolyl isomerase Pin1 is highly conserved and has been linked to 
important roles in numerous cellular processes including differentiation, cell 
proliferation, the immune response, and also Alzheimerʼs disease. Among the known 
substrates are β-catenin, c-Myc, cyclins, tau and p53, which are all involved in fate 
determining pathways in the cell (Lu et al., 2007; Yeh et al., 2007)). The p53 protein 
is widely known as the guardian or gatekeeper of the genome because of its crucial 
role in coordinating cellular responses to genotoxic stress (Lane, D.P., 1992; Levine, 
A.J., 1997). The tumor suppressor function of p53 relies on its transcriptional activity, 
which is modulated by several interactions with regulatory proteins, although the 
precise mechanism of p53 induced activation is not fully understood, they are 
generally thought to involve post-translational modifications, including acetylation, 
SUMOylation, phosphorylation and ubiquitylation. Interestingly, the prolyl isomerase 
Pin1 has a central role in transducing phosphorylation of p53 into conformational 
changes that affect p53 stability and function (Ryo et al., 2002; Zhang et al., 2002; 
Zacchi et al., 2002). However, less clear from these studies is how Pin1 affects p53 
function and stabilization. Thus we wondered whether Pin1, in analogy to its role in 
the OLE pathway, might as well regulate the degree of p53 ubiquitylation and thereby 
the fate of p53 in cells. 
 
 
4.4.1 Influence of Pin1 on p53 ubiquitylation in vivo 
 
To address the question whether p53 is regulated analogous to Spt23 in the OLE 
pathway we investigated the influence of Pin1 on p53 ubiquitylation and stability in 
vivo in mammalian wild-type p53 containing U2-OS cells. 
In early studies it was shown that the p53 steady state level was reduced 
upon treatment of cells with the Pin1 inhibitor juglone (5-hydroxy-1,4-naphtoquinone; 
Paulsen & Ljungman, 2005), but without addressing the mechanistic details of Pin1 
as a PPiase and its possible impact on p53 regulation. In U2-OS cells, p53 was 
found to be predominantly unmodified, but a minor fraction was ubiquitylated by 
usually not more than four ubiquitin moieties, corresponding to 
mono/oligoubiquitylated p53. Taking advantage of the Pin1 inhibitor juglone, U2-OS 
cells were treated either with 5 µM or 10 µM juglone for 2 h or with 5 µm juglone for 
Results 
42 
different timepoints. Treating the U2-OS cells with juglone surprisingly resulted in the 
appearance of a diffuse population of higher molecular mass forms of p53. In 
contrast, the pool of mono/oligoubiquitylated species of p53 disappeared, suggesting 
increased polyubiquitylation of p53 by Pin1 inhibition (Figure 20a, upper panel). 
Notably, the induction of p53 polyubiquitylation by juglone was dose (increasing 
concentration) and time dependent and was in both cases accompanied by lower 
steady state levels of p53 as indicated by quantifications of p53 steady state (Figure 
20a, lower panels). 
 
 
Figure 20. Pin1 controls the degree of p53 ubiquitylation in vivo. (a) Pin1 inhibition by 
juglone induces p53 polyubiquitylation and degradation. U2OS cells were either untreated or 
treated with 5 or 10 μM juglone for 2 h (left), or with 5 μM juglone for the time indicated (right). 
Cell lysates were subjected to immunoblot analysis for p53 (upper and middle panels) or 
MEK-1 as a control (lower panel). The middle panel shows a weaker exposure of the p53 blot 
to reveal p53 decay upon juglone treatment together with the quantification (initial level set as 
1.0). Pools of oligo- (oligo-Ub) and polyubiquitylated (poly-Ub) p53 are indicated. (b) 
Specificity of juglone for Pin1. U2OS cells were transiently transfected with His-tagged 
ubiquitin (HISUb) in combination with increasing amounts of Pin1. 72 h after transfection, cells 
were either left untreated or treated with 5 μM juglone for 2 h and lysates were subjected to 
Ni-NTA pull-down to isolate ubiquitin-conjugates. This material was analyzed by 
immunoblotting using an antibody specific for p53 (DO-1; first panel and p53 Input). Inputs for 
p53, Pin1, and MEK-1 (loading control) are shown by immunoblots. Cells not treated with 
juglone (left panels) express either HA-tagged (lane 1) or His-tagged ubiquitin (lane 2). (The 
figure represents data of one gel.) Note that Pin1 overexpression reverts the juglone-induced 
effects on p53 ubiquitylation and protein levels (quantification is shown above; p53 levels 
without juglone treatment is set as 1.0).  
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Juglone was described to act in a stoichiometric way on inhibiting Pin1 
(Hennig et al., 1998). Hence, by increasing the amount of Pin1 by Pin1 
overexpression in juglone treated cells we should be able to reverse the juglone-
induced p53 polyubiquitylation and restore p53 stability. To perform this experiment, 
U2-OS cells were transfected with His-tagged ubiquitin (HIS-Ubi, or HAUbi as a control) 
in combination with increasing amounts of WT Pin1. After juglone treatment cells 
were harvested and lysates were subjected to denaturing Ni-NTA pull-down to isolate 
ubiquitin-conjugates. Importantly, the observed effect of juglone on p53 
polyubiquitylation in vivo was indeed specific for Pin1, as it could be completely 
repressed by additionally overexpressing Pin1 in juglone treated cells in a dosage 
dependent manner (Figure 20b, upper panel). Furthermore, juglone treatment 
resulted in a significant decrease of celluar p53 levels which were again stabilized 
upon Pin1 overexpression (Figure 20b, p53 Input levels).  
Beause p53 levels are controlled by nuclear degradation and 
monoubiquitylation of p53 serves as a signal for p53 nuclear export (Li et al., 2003; 
Brooks et al., 2004), we followed the fate of p53 in cells by immunofluorescence 
microscopy. As expected, p53 was readily detected in the nucleus under normal 
conditions in U2-OS cells (Figure 21a, two upper panels).  
 
 
 
Figure 21. Pin1 controls the degree of p53 ubiquitylation in vivo. (a) Pin1 controls p53 
levels in vivo. Immunofluorescence microscopy of cells using an anti-p53 antibody (DO-1) 
antibody. DAPI staining visualizes the nucleus. Cells were either untreated (Control), treated 
with the proteasome inhibitor MG132, juglone, or both. The graph shows the quantification of 
the data. The numbers represent p53-positive cells showing nuclear localization relative to the 
total number (in average 200) of cells counted. 
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However, upon treatment with the Pin1 inhibitor juglone, p53 disappeared 
dramatically, suggesting rapid degradation. Remarkably, when these cells were 
pretreated with the proteasome inhibitor MG132 and then the Pin1 inhibitor juglone 
was applied, p53 again accumulated in the nucleus, indicating that juglone-induced 
p53 polyubiquitylation indeed targets the protein to nuclear degradation (Figure 21a, 
also see quantification). In conclusion, these data demonstrate that Pin1 regulates 
p53 levels in vivo through inhibition of ubiquitin-dependent degradation in cells. 
 
 
4.4.2 Influence of Pin1 on p53 ubiquitylation in vitro 
 
Recent studies demonstrate a differential control of p53 activity by Mdm2: whereas 
low levels of Mdm2 activity induce monoubiquitylation and nuclear export of p53, high 
Mdm2 levels promote p53 polyubiquitylation and nuclear degradation (Li et al., 2003; 
Brooks et al., 2006).  
We established an in vitro ubiquitylation system for p53 to directly test the 
influence of Pin1 on the degree of p53 polyubiquitylation. We therefore employed p53 
in vitro ubiquitylation assays using two approaches: we either used purified, 
recombinant p53 (Figure 22 a-c), or p53 expressed in a coupled in vitro 
transcription/translation system (p53 IVT; Figure 23a, b). As was previously shown, 
polyubiquitylation of p53 in vitro is efficiently triggered by high levels of the p53-
specific E3 ligase Mdm2 (Figure 22a; Li et al., 2003), we therefore used high Mdm2 
levels in the in vitro ubiquitylation assays to effectively trigger p53 polyubiquitylation 
and then tested the direct influence of recombinant Pin1 or a Pin1 mutant in this in 
vitro system.  
Remarkably, pre-incubation of p53 with recombinant Pin1 strongly inhibited 
this Mdm2-dependent reaction (Figure 22b). Interestingly p53 polyubiquitylation 
negatively correlated with the amount of Pin1 added to the reaction, whereas the 
addition of an inactive Pin1 mutant variant had no influence on the p53 
polyubiquitylation levels (Figure 22c).  
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Figure 22. Pin1 controls the degree of p53 ubiquitylation in vitro. (a) Polyubiquitylation of 
recombinant p53 in vitro is triggered by high concentrations of Mdm2. Recombinant p53 was 
incubated with ubiquitin (Ub), mammalian E1, E2 (UbcH5), ATP, and increasing amounts of of 
E3 (Mdm2, lane 5 – 8, 0 - 202.5 ng) to induce p53 polyubiquitylation. A lysine-less ubiquitin 
variant (UbK0) that fails to form polyubiquitin chains (lanes 2, 4 and 9) was used to control for 
p53 polyubiquitylation. Polyubiquitylated p53 (poly-Ub) is detected by immunoblotting with 
FK2 antibodies (upper panels). Oligoubiquitylated p53 (Ub) was detected by DO-1 antibodies 
(lower panels). The high concentration of Mdm2 that leads to p53 polyubiquitylation (lane 8) 
was used for the experiments shown in Figure 22b, c. (b) Pin1 inhibits polyubiquityation of 
p53 in an in vitro assay with recombinant proteins. Recombinant p53 (lane 2-4) was either 
pre-incubated (1h, 4°C) with recombinant Pin1 (lane 4), or GST (lane 3), respectively and 
then incubated with ubiquitin (Ub), mammalian E1, E2, ATP, and high concentration of E3 
(Mdm2) that induces p53 polyubiquitylation (Figure 22a, lane 8). Lane 1 represents a control 
reaction without p53 (recombinant GST was used instead) to show that the observed 
polyubiquitin conjugates (detected by the FK-2 antibody in lane 2-4 upper panel) are 
conjugates with p53. Polyubiquitylated p53 (poly-Ub) is detected by immunoblotting with FK2 
antibodies (upper panels). Oligoubiquitylated p53 (Ub) was detected by DO-1 antibodies 
(lower panels). The quantification below refers to the level of polyubiquitylated p53 detected 
by the FK2 antibody (upper panel). (c) Pin1 inhibits polyubiquityation of p53 in an in vitro 
assay with recombinant proteins. Recombinant p53 was preincubated (1h, 4°C) with either 
GST (controls, lanes 1 and 8), increasing amounts of recombinant Pin1 (Pin1, lane 2 - 4), or a 
Pin1 mutant variant (Pin1mut, lanes 6 and 7), respectively and then incubated with ubiquitin 
(Ub), mammalian E1, E2, ATP, and a high concentration of E3 (Mdm2) that induces p53 
polyubiquitylation (Figure 22a, lane 8). A lysine-less ubiquitin variant that fails to form 
polyubiquitin chains (UbK0, lane 8 - 10) was used to control for p53 polyubiquitylation (right 
panels). Figure 20b, Lane 1 represents a control reaction without p53 (recombinant GST was 
used instead) to show that the observed polyubiquitin conjugates (detected by the FK-2 
antibody in the upper panel) are conjugates with p53. Polyubiquitylated p53 (poly-Ub) is 
detected by immunoblotting with FK2 antibodies (upper panels). Oligoubiquitylated p53 (Ub) 
was detected by DO-1 antibodies (lower panels). The quantification below refers to the level 
of polyubiquitylated p53 detected by the FK2 antibody (upper panel). 
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Due to the fact that Pin1 is a phosphorylation driven peptidyl-prolyl cis/trans 
isomerase we conducted further p53 in vitro ubiquitylation assays with p53 
expressed in a coupled in vitro transcription/translation system (p53 IVT), in such a 
system all necessary p53 modifications can take place (Figure 23a). Notably, also in 
this setup recombinant Pin1 efficiently inhibited the Mdm2-dependent 
polyubiquitylation reaction in a dose-dependent manner (Figure 23b). By contrast, 
addition of an inactive Pin1 variant had again no influence on p53 ubiquitylation 
levels. To test the reactivity of the FK2 antibody to specifically detect p53 
polyubiquitylation, all in vitro ubiquitylation reactions were additionally performed 
using a lysine-less ubiquitin variant that fails to form polyubiquitin chains (UbK0) and 
indeed FK2 reactivity was only observed with WT ubiquitin. 
These findings strongly suggest that Mdm2 and Pin1 exert opposing effects 
on p53 polyubiquitylation and indicate that the two proteins are possibly rivals in 
cells. 
 
 
 
Figure 23. Pin1 controls the degree of p53-IVT ubiquitylation in vitro. (a) Titration of the 
amount of p53 expressed in a coupled transcription-translation system (p53 IVT) used for in 
vitro ubiquitylation assays. High amounts of E3 (Mdm2, lane 1-4) was incubated with ubiquitin 
(Ub), mammalian E1, E2 (UbcH5), ATP, and decreasing amounts of p53 IVT to induce p53 
IVT polyubiquitylation. Polyubiquitylated p53 (poly-Ub) is detected by immunoblotting with 
FK2 antibodies (upper panels). Oligoubiquitylated p53 (Ub) was detected by DO-1 antibodies 
(lower panels). The concentration of p53 IVT that leads to p53 mono- and robust 
polyubiquitylation (lane 4) was used for the experiments shown in Figure 23b.  
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Figure 23 continued  
 
(b) In vitro ubiquitylation of p53 expressed in a coupled transcription-translation system. In 
vitro translated p53 (IVT p53; see Figure 23a) was preincubated (1 h, 4°C) either with GST, 
increasing amounts of recombinant Pin1 wild-type or Pin1 mutant (same as in Figure 22c). 
Ubiquitylation reaction was done with E1, E2, high E3 and ATP as in Figure 20c. Pools of 
oligo- (Ub) and polyubiquitylated (Poly-Ub) p53 (in vitro translated) are indicated. Shown are 
immunoblots developed with FK2 antibodies specific for polyubiquitylated proteins (top panel) 
and anti-p53 antibodies (DO-1; lower panel). The quantification refers to the level of 
polyubiquitylated p53 detected by the FK2 antibody. A lysine-less ubiquitin variant that fails to 
form polyubiquitin chains (UbK0) was used to control for p53 polyubiquitylation (right panel, 
last lane). 
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5 Discussion  
 
The diversity and functional repertoire of an organismʼs proteome is extended greatly 
by means of covalent post-translational modifications. Since the discovery of ubiquitin 
in the mid-1970s, the covalent attachment of ubiquitin to protein substrates is the 
classical and so far best understood example of targeting proteins for degradation. 
The canonical view of the ubiquitylation cascade is, however, oversimplified. The 
ability to form a polyubiquitin chain depends on the type of the ligase (e.g. whether it 
acts processively) or even on the substrate. However, the switch from 
mono/oligoubiquitylation to polyubiquitylation (termed here polyubiquitylation 
switching) is much more complex and stems from the existence of a large number of 
enzymes and auxiliary factors that finally catalyze the polyubiquitylation reaction 
resulting in either proteolytic or non-proteolytic function.  
The most important finding of this study is that the peptidyl-prolyl cis/trans 
isomerase Pin1 regulates the degree of substrate ubiquitylation. Pin1 acts directly at 
the heart of the ubiquitylation reaction and represents a completely different 
mechanism of polyubiquitylation switching. Pin1 most likely acts by translating the 
induced structural change (“kink”) in a substrate into a change of E3 ligase affinities 
and therefore presents a so far unrecognized regulatory mechanism in the ubiquitin 
pathway. 
 
 
5.1 Peptidyl-prolyl cis/trans isomerases 
 
In folded proteins, peptidyl-prolyl peptides have the unique property of existing in two 
distinct isomers, cis or trans. This property provides a potential backbone switch in 
the polypeptide chain and can be controlled by cis/trans isomerization. This 
intrinsically slow conversion is catalyzed by a ubiquitous class of enzymes termed 
peptidyl-prolyl cis/trans isomerases (PPIases), which can be divided into three major 
families: the cyclophilins and the FK506-binding proteins (FKBPs), also called 
conventional PPIases and additionally a recently identified third family of PPIases, 
which can be further subdivided into two subfamilies based on their substrate 
specificity, parvulin-type and Pin1-type PPiases. Although structurally unrelated in 
their primary sequences and three-dimensional structures, all PPIases are able to 
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catalyze a similar reaction (Lu et al., 1999). Furthermore, a role for PPIases in folding 
of newly synthesized proteins was implied and indeed chaperone-like activity has 
been associated with several PPIases (Kruse et al., 1995; Schmid, 1995).  
Isomerization of S/T-Pro bonds between cis and trans can alter the local, and 
even the global protein structure. The structural difference between the two isoforms 
(cis/trans) also constitutes a fundamental molecular change that might be translated 
into different functional states, or distinguish between intermolecular binding partners 
(Figure 24). In fact peptidyl-prolyl cis/trans isomerases form a special class of 
enzymes in many respects, because unlike most other post-translational 
modifications cis/trans isomerization is a non-covalent post-translational modification. 
 
 
 
Figure 24. The conformation and regulation of proline-directed cis/trans isomerization. 
Proline is unique among amino acids in its ability to adopt either the cis or trans state, due to 
its five-membered ring in the peptide backbone. Peptidyl-prolyl isomerases catalyze the 
intrinsically rate-limiting process  Based on substrate specificity, PPIases can be divided into 
(a) phosphorylation-indipendent, Cyclophilins and FKPBs and (b) phosphorylation-dependent 
enzymes, Pin1 and Pin1-type enzymes. 
 
The reversible phosphorylation of proteins on Ser/Thr residues immediately 
preceding Pro (S/T-Pro) is a major regulatory mechanism. Remarkably, 
phosphorylation of S/T-Pro motifs not only further slows the uncatalyzed proline 
conversion from cis to trans, it furthermore renders the peptide bond resistant to the 
catalytic action of the two conventional PPIases (cyclophilins and FKBPs) and 
parvulin-type PPIases. The Pin1-type PPIases are so far the only known PPIases 
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that are specific for phosphorylated S/T-Pro bonds (Yaffe et al., 1997; Ranganathan 
et al., 1997; Lu et al., 2002).  
The conventional PPIases, cyclophilins and FKBPs, play a fundamental role 
in the regulation of several cellular processes including the immune-response. 
Surprisingly, all known members of the cyclophilins and FKBP family can be entirely 
disrupted without any significant phenotype. In fact, evidence for the biological 
importance of the enzymatic activity in these PPIases remains elusive (Lu et al., 
1996; Dolinsky et al., 1997). 
By contrast, Pin1 and its homologs have a well-defined function in 
phosphorylation signaling by specifically targeting phosphorylated S/T-Pro bonds, an 
activity that cannot be effectively catalyzed by conventional or parvulin-type PPIases. 
Furthermore, the requirement of substrate phosphorylation for Pin1-type PPIases 
isomerization reveals an additional level of regulation and specificity, coupling the 
isomerization activity to the tightly controlled activities of proline-directed kinases 
(and phosphatases). This phosphorylation specificity implies that Pin1 plays a unique 
role in the regulation of signaling cascades that function via proline-directed 
phosphorylation (Figure 24).  
Notably, Pin1 was reported to be subject of post-translational modification 
itself. Pin1 PPIase catalytic activity is modulated via phosphorylation at S16, which 
lies in the center of the phspho-binding pocket of its WW domain and prevents Pin1 
interaction with its substrate (Lu et al., 2002) and demonstrates an additional 
mechanism for regulation of the phosphorylation-specific isomerase Pin1. 
 
 
5.2 Pin1 acts a fate switch in the UPS: 
mono/oligoubiquitylation versus polyubiquitylation 
 
Polyubiquitin-chain assembly is usually a processive reaction that requires the 
canonical ubiquitin conjugation machinery E1, E2, E3. However, the process of 
polyubiquitylation switching (mono/oligoubiquitin to polyubiquitin) is mediated by a 
variety of dedicated factors that mediate ubiquitin chain elongation. Enzymes 
possessing the specific activity to catalyze polyubiquitin-chains in collaboration with 
E1, E2 and E3 had been coined E4 enzymes (Hoppe et al., 2005). It seems likely 
that these different mechanisms to switch from mono/oligoubiquitylation to 
polyubiquitylation are exploited under distinct physiological settings and must be 
Discussion 
51 
therefore tightly regulated. Certain substrates (e.g. Spt23 or p53) are 
mono/oligoubiquitylated by an archetypical E3, which might alone only have a low 
affinity or processivity and therefore catalyze a mono/oligoubuquitin reaction (e.g. 
Rsp5 or Mdm2). In an additional reaction the E4 enzyme, which serves as a 
processivity factor, then polyubiquitylates the substrate with a K48-linked chain, 
which subsequenty results in substrate degradation. Another strategy for a 
polyubiquitylation switch can be found in the regulation of PCNA (proliferating-cell 
nuclear antigen), PCNA associates with various DNA polymerases and functions as 
a sliding clamp, stimulating accurate and processive DNA synthesis. In addition, 
PCNA appears to function as a platform for accessory factors. Here the switch from 
mono- to polyubiquitylation involves two ubiquitin-conjugating enzymes, Rad6 and 
Ubc13/Mms2, and two ubiquitin ligases, the RING-finger proteins Rad18 and Rad5. 
Upon DNA-damage, PCNA is monoubiquitylated by a Rad6/Rad18 heterodimer. By 
contrast, PCNA polyubiquitylation requires in addition the heterodimeric E2 
Ubc13/Mms2 and the E3 ligase Rad5, which leads to a K63-linked polyubiquitin 
chain (Hoege et al., 2002). Another variation of this theme is found with the ubiquitin 
ligase APC/C, which involves a specific E2 for monoubiquitylation but another E2 for 
polyubiquitin chain elongation (Rodrigo-Brenni et al., 2007). 
This study describes a completely different mechanism of polyubiquitylation 
switching, which involves the highly conserved peptidyl-prolyl isomerase (PPIase) 
Pin1. Among the PPIases, Pin1 is special as its association with substrates involves 
a highly conserved WW protein-interaction domain that recognizes preferentially 
phosphorylated serine-proline or threonine-proline motifs (pS/T-Pro motifs; “proline-
directed phosphorylation”). Due to this special control, Pin1 often functions as a 
regulated binary switch in fate-determining pathways (Lu et al., 2007; Yeh et al., 
2007). Notably, Pin1 has been linked to differentiation, cell proliferation, the immune 
response, and also Alzheimerʼs disease (Takahashi et al., 2008; Lu et al., 2007; 
Shaw, P.E., 2007). Among the known substrates are celebrities like p53,  Cdc25, c-
Myc, cyclins, and tau. Pin1-induced conformational changes are translated into a 
variety of responses, including substrate degradation. Indeed, Pin1 is often linked to 
the UPS, but how Pin1 controls protein stability remained unclear.  
By studying two cellular key regulators, the mammalian tumor suppressor p53 
and the NFκB-related transcription factor Spt23 of yeast, this study shows that the 
activity of Pin1 crucially influences the degree of substrate polyubiquitylation (Figure 
18-23). This work demonstrates that in these two cases, high Pin1 activity supports 
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weak substrate ubiquitylation largely in the form of mono/oligoubiquitylation. By 
contrast, low Pin1 activity stimulates massive induction of polyubiquitylation and 
leads to subsequent proteasome dependent degradation (Figure 18-23), illustrating 
the fundamental importance of a polyubiquitylation switch for signal transduction. 
 
 
5.2.1 Pin1 controls the degree of Spt23 ubiquitylation in the OLE 
pathway 
 
Recent studies have shown that Spt23 (and its relative Mga2) is synthesized as 
inactive, ER-membrane-anchored transcription factors of OLE1, encoding fatty acid 
desaturase. Upon fatty acid restriction, Spt23 becomes activated by proteasomal 
processing, which eliminates the C-terminal membrane anchor of Spt23 by ERAD. 
The N-terminal, processed form then translocates into the nucleus and drives OLE1 
transcription (Hoppe et al., 2000; Rape et al., 2001). Efficient proteasomal processing 
requires low levels of Spt23 ubiquitylation in the form of mono/oligoubiquitylation 
catalyzed by the WW domain containing HECT E3 ligase Rsp5. Binding of Rsp5 to 
Spt23 involves one of the enzymeʼs three WW domains (Hoppe et al., 2000).  
Intriguingly, Pin1 (termed Ess1 in yeast) using its WW domain binds 
apparently to the same region in Spt23 (Figure 7). However, in contrast to Rsp5, Pin1 
binding strictly depends on the phosphorylation of pS-Pro sites of Spt23 (Figure 9, 10 
and 25). In addition, CK2 was found as a strong binding partner of Spt23 in vivo 
(Figure 11) and it could be demonstrated that binding of Ess1 to Spt23 is stimulated 
by CK2-mediated phosphorylation of the transcription factor (Figure 11-13), 
concluding that Spt23 phosphorylation is an essential prerequisite for Ess1 binding 
and PPIase activity.  
Mammalian Pin1 was reported to be subject of post-translational modification 
by S16-directed phosphorylation. Furthermore, the phosphorylation status was linked 
to Pin1 activity and localization, but the biological relevance of this modification was 
largely elusive (Lu et al., 2002). This study demonstrates that also the 
phosphorylation status of yeast Ess1 S16 is directly linked to the PPIase activity and 
additionally subcelluar localization of Ess1 in the cell(Figure 14 and 15). Remarkably, 
the phosphorylation status of Ess1 S16 is directly linked to viability in S. cerevisiae 
(Figure 14b).  
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Hence, post-translational modification of Ess1 by S16 phosphorylation might 
represent an additional mechanism, critical for regulating WW domain S/T-Pro 
binding activity and Ess1 PPIase, which is especially interesting with regard to a 
putative additional regulatory function in the OLE pathway.  
 
 
 
Figure 25. Proline-directed Spt23 phosphorylation mediates specificity for Pin1-
mediated cis/trans isomerization. (a,b) Proline-directed phosphorylation of Spt23 (S/T-Pro) 
stimulated by CK2 is a prerequisite for Pin1-mediated cis/trans isomerization of the Spt23 
precursor and thereby connects proline-directed phosphorylation and ubiquitylation and 
results in subsequent processing by the 26S proteasome (see also Figure 4). 
 
Pin1 deletion in S. cerevisiae is lethal, but interestingly, cells survive if 
unsaturated fatty acids are provided exogenously or OLE1 was expressed (Figure 5 
and 7). Conversely, Pin1 overexpression results in a disproportionate up-regulation of 
Ole1 activity and is toxic for cells. Notably, this growth defect was even exacerbated 
by addition of unsaturated fatty acids to the medium (Figure 8). Pin1 loss in yeast led 
to complete Spt23 p120 precursor degradation (Figure 14) and Pin1 activity was 
directly correlated with p120 stability (Figure 14). In addition, Spt23 precursor stability 
could be directly linked to the Ess1 binding site in Spt23 (Figure 14 and 15). 
The reason for the lethality of yeast Pin1 mutants is that Pin1 loss triggers 
massive Spt23 precursor polyubiquitylation, leading to its complete elimination by 
ERAD (Figure 14; Figure 16 and 17). Thus, Pin1 acts on Spt23 directly at the level of 
substrate ubiquitylation: high (normal) Pin1 activity activates the OLE pathway 
through mono/oligoubiquitylation and proteasomal processing; low Pin1 activity 
triggers Spt23 polyubiquitylation followed by ERAD (Figure 25 and 26).  
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Figure 26. Simplified scheme of Spt23 ubiquitylation and the opposing activities of the 
peptidyl-prolyl cis/trans isomerase Pin1. (a) Pin1 acts as a binary switch directly at the 
level of substrate ubiquitylation: high (normal) Pin1 activity activates the OLE pathway through 
mono/oligoubiquitylation and proteasomal processing, whereas in contrast low Pin1 activity 
triggers Spt23 polyubiquitylation and degradation. 
 
Membrane homeostasis and regulation of membrane composition of 
eukaryotic membranes is highly dynamic. Membrane fluidity in S. cerevisiae is largely 
controlled by the activity of the essential Δ9-fatty acid desaturase enzyme Ole1, 
which is a key enzyme in lipid and membrane synthesis pathways regulating the 
amount of unsaturated fatty acids in the cell. The importance of the homeostasis of 
fatty acid pools and the functional integrity of the cellular vesicular systems is 
reflected by the fact that low levels of unsaturated fatty acids result in a severe 
impairments of the cellular membrane systems. How a change in membrane fluidity 
is sensed and transduced to regulate the transcription factor Spt23 that activates 
Ole1 in the OLE pathway is still enigmatic. The discovery that Pin1 acts by controlling 
the degree of substrate ubiquitylation and is thereby directly involved in the decision 
between proteasomal processing (RUP) versus proteasomal degradation reveals a 
so far unrecognized role of this PPIase in the OLE pathway and an interesting new 
level of complexity (Figure 25 and 26). However, it seems unlikely that CK2-mediated 
phosphorylation of Spt23 and subsequent Pin1-induced cis/trans isomerization is 
directly triggered by a change in membrane homeostasis. Interestingly, mRNA levels 
of both Spt23 and Mga2 were shown to be upregulated by the unfolded protein 
response (UPR) and Spt23 precursor processing is induced upon heat stress 
(Travers et al., 2000). Additionally, considering the drastic changes in membrane 
fluidity and composition in response to e.g. cell growth suggests that it is more likely, 
that the membrane-bound Spt23 precursor p120 or a membrane-associated protein 
functions as the sensor of membrane composition. A change in membrane fluidity or 
composition might induce a proline-directed (S/T-Pro) phosphorylation in Spt23, 
which thereby triggers an association of Spt23 with the peptidyl-prolyl isomerase 
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Ess1 and subsequently with the processing machinery. The special requirement of 
substrate phosphorylation for Ess1-mediated cis/trans isomerization uncovers an 
additional level of regulation and specificity, coupling the isomerization activity to the 
tightly controlled activities of proline-directed kinases (Figure 9-13 and Figure 25) and 
furthermore upstream signaling.  
 
 
5.2.2 Pin1 acts by regulating the degree of p53 ubiquitylation 
 
The influence of Pin1 on p53 ubiquitylation lies at the heart of the regulation of the 
tumor suppressor p53. The ubiquitin ligase Mdm2 controls p53 stabilization and is 
one of the best characterized ubiquitin ligases. Mdm2 catalyzes normally 
mono/oligoubiquitylation of p53, apparently because it quickly dissociates from the 
substrate after adding a single ubiquitin molecule to it (Lai et al., 2001). However, in 
vitro and in vivo, high levels of Mdm2 have been shown to trigger strong p53 
polyubiquitylation (Figure 22 and 23; Li et al., 2003; Brooks et al., 2004). Pin1 was 
previously shown to bind p53 and to have an influence on p53 stability (Zacchi et al., 
2002; Zheng et al., 2002; Mantovani et al., 2004). However, how Pin1 controls p53 
turnover was still largely enigmatic. 
 
 
 
 
Figure 27. Simplified scheme of p53 ubiquitylation and the opposing activities of the 
ubiquitin ligase Mdm2 and Pin1. (a) Low Mdm2 levels induce mono/oligoubiquitylation of 
p53 whereas increasing Mdm2 levels (rising slope) promote robust p53 polyubiquitylation. (b) 
Pin1 activity, by contrast, reduces p53 polyubiquitylation, but lowering Pin1 levels (descending 
slope) stimulates p53 polyubiquitylation and nuclear degradation.  
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Intriguingly, the data presented here show that inhibition of Pin1 (e.g. by 
juglone) results in robust p53 polyubiquitylation in vivo (Figure 20), which 
subsequently leads to nuclear proteasomal degradation (Figure 21). The 
consequences of the Pin1-controlled polyubiquitylation switch are particularly striking: 
mono/oligoubiquitylation leads to p53 nuclear export, whereas p53 polyubiquitytation 
triggers its rapid degradation (Figure 21; Brooks et al., 2004). 
The direct influence of Pin1 on p53 polyubiquitylation was independently 
confirmed by employing two p53 in vitro ubiquitylation systems either with purified, 
recombinant p53 (Figure 22), or p53 expressed in a coupled in vitro 
transcription/translation system (Figure 23). As noted previously (Li et al., 2003), 
Mdm2 can efficiently trigger p53 polyubiquitylation if present at high levels. 
Remarkably, in experimental setups Pin1 strongly inhibited this Mdm2-dependent 
reaction in a dose-dependent manner, whereas an inactive Pin1 variant had no 
influence (Figure 22 and 23).  
Hence, Mdm2 and Pin1 are both fundamental for balancing p53 levels, yet in 
clearly opposing ways (Figure 21-23 and 27). These findings indicate that Mdm2 and 
Pin1 do indeed exert opposing effects on p53 polyubiquitylation and furthermore 
suggest that the two proteins may antagonize each otherʼs function in cells. 
 
 
5.2.3 Mechanism of Pin1-induced polyubiquitylation switching 
 
Previous work has shown that switching mono/oligoubiquitylation to polyubiquitylation 
can be achieved by a dedicated E4 enzyme, that assembles polyubiquitin chains on 
a pre-existing ubiquitin modification, or by specific pairs of E3 ubiquitin ligases, which 
together catalyse polyubiquitylation. This work demonstrates that Pin1, through its 
PPIase activity, can also decisively regulate the ubiquitylation status of a substrate. 
Thus in contrast to the regulation by E4 enzymes, Pin1 seems to act earlier, directly 
at the level of the E3. Notably, due to the fact that substrate phosphorylation (pS/T-
Pro) is a prerequisite for Pin1 binding, the switch from mono/oligoubiquitylation to 
polyubiquitylation has the additional advantage of being highly specific and precisely 
regulated. 
How Pin1 influences polyubiquitylation is currently unclear due to the lack of 
structural data. Interestingly, in the case of the Spt23 the same E3 ligase (Rsp5) 
seems to either monoubiquitylate Spt23 leading to processing of the precursor, or in 
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the absence of Pin1, promotes polyubiquitylation and degradation of the same 
substrate. This suggests that the action of the PPIase Pin1 might most likely change 
the affinity or processivity of the E3 ligase. Notably, Spt23 might represent a special 
case of regulation: both Rsp5 and Ess1 have WW substrate-interaction domains and 
not only target Spt23 via this domain (Figure 7b); in fact binding seems to be partially 
competitive (Figure 7c). By contrast, the RING E3 ligase Mdm2 does not belong to 
the family of WW domain-containing E3s, and therefore binding of Mdm2 and Pin1 
are most likely not competitive reactions. Hence, it seems more plausible that 
peptidyl-prolyl cis/trans isomerization in a substrate introduces a structural change 
that might directly influence ubiquitin ligase affinities.  
Given the fundamental importance of p53 for tumor biology, it will be crucial to 
test how Pin1 collaborates with other p53-directed E3s. Mdmx for example has been 
described to enhance p53 ubiquitylation by altering the substrate preference of the 
Mdm2 ubiquitin ligase (Okamoto et al., 2009) or p53ʼs interplay with the 
acetyltransferase p300, which acts as an E4 enzyme in the cytosol to promote p53 
polyubiquitylation (Dingding et al., 2009). 
Hence, future objectives are to understand how Pin1-mediated cis/trans 
isomerization leads to a change in E3 affinities or processivity. One way to test this 
hypothesis is to directly measure E3 ligase affinities in in vitro experiments in the 
presence or absence of Pin1 or Pin1 mutant variants (e.g. in surface plasmon 
resonance (SPR) experiments). Furthermore, by changing the affinities of the E3 
ligase towards a substrate by either enhancing or decreasing the binding properties 
(e.g. screening for E3 ligase mutant variants) one might be able to circumvent the 
requirement for Pin1 cis/trans isomerization. Finally, changing the substrate 
polypeptide-backbone to “lock” a substrate in a particular conformation (cis or trans) 
would be an interesting tool to study E3 binding properties and ubiquitylation 
processivity. 
 
 
5.2.4 General implications of Pin1-mediated cis/trans isomerization in 
regulatory pathways 
 
Pin1 overexpression was observed in several types of cancer where it functions to 
promote tumorigenesis induced by oncogenes (e.g. Ras and Neu), additionally Pin1 
overexpression shows a correlation with poor clinical prognosis (Lu et al., 2003; Finn 
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and Lu, 2008). Consequently, Pin1-mediated phosphorylation-dependent 
isomerization represents a unique regulatory mechanism in cell signaling and 
therefore Pin1 was discussed as a novel diagnostic marker (Finn and Lu, 2008). The 
fact that Pin1 is predominantly overexpressed in several human tumors including 
breast, colorectal and prostate cancer (Wulf et al., 2001; Ayala et al., 2003; Kim et 
al., 2005) makes it a potential therapeutic target for cancer treatment. 
Pin1 is known to act on numerous substrates, in particular regulatory proteins 
in fate determining pathways. When considering for example the p53 gene family, 
recent data now links the p53 sibling p73 with Pin1 in apoptosis (Mantovani et al., 
2004). Interestingly, also in this case the Pin1-p73 interaction is phosphorylation-
dependent. Additionally loss of Pin1 seems to destabilize p73, which strongly 
suggests that p73 might be regulated by a similar principle by Pin1 as it does for 
Spt23 and p53 by regulating the degree of ubiquitylation. Pin1 may even function to 
assemble and stabilize a transcriptional complex involving all members of the p53 
family, including p53, p63 and p73 together with other cofactors. Intriguingly, also 
p63 has several conserved S/T-Pro sites and future experiments may hopefully 
explore this exciting prospect, especially if p63, as the third member of the p53 family 
might be a Pin1 substrate as well.  
As Pin1-mediated cis/trans isomerization is a phosphorylation-dependent 
regulatory mechanism, Pin1 is also involved in cell cycle regulation. Pin1 targets key 
proteins such as cyclin D1 or Cdc25, which is a mitotic inducer phosphatase that 
controls the activation of Cdc2/cyclin B protein kinase and entry into mitosis in 
eukaryotic cells. Phosphorylation-induced isomerization of Cdc25 by Pin1 appears to 
mediate a conformational change within the regulatory domain of Cdc25, affecting its 
catalytic activity (Hutchins et al., 2004). Due to the important role that Cdc25 plays in 
response to genotoxic stress, particularly in cancer cells defective in p53 regulation, it 
will be crucial to review the regulation of Cdc25 with regard to Pin1ʼs new role as a 
fate switch in the UPS.  
Cancer and Alzheimer's disease (AD) are two common disorders for which 
the final pathophysiological mechanism is not yet clearly defined. Interestingly, Pin1 
is downregulated in degenerative neurons of Alzheimerʼs disease (AD) patients and 
Pin1 deletion in mice leads to age-dependent neurodegeneration (Lu et al., 2004). 
Pin1 was described as the molecular partner for tau and amyloid precursor protein 
(APP), the key factors of Alzheimer's disease (AD). Pin1 binds to and isomerizes a 
pThr-Pro motif in amyloid precursor protein (APP) to promote non-amyloidogenic 
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APP processing and to reduce Aβ production. Pin1 was shown to interact with 
hyperphosphorylated tau protein and regulates its activity to bind microtubules. 
Remarkably, S/T-Pro directed phosphorylation of tau has been directly linked to tau 
stability (Lim et al., 2008), how and whether tau stability might be linked to the UPS 
via a Pin1-mediated change in the degree of substrate ubiquitylation is so far unclear.  
Although Pin1 is known to influence other events (for example 
phosphorylation) as well, we propose that Pin1-induced cis/trans isomerization is 
often translated into a change in ubiquitylation status. Hence, it will be important to 
review other known Pin1 substrates and ask whether this polyubiquitylation switch is 
a recurring theme and central for cellular regulation. 
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6 Materials and Experimental Methods 
 
The subsequent microbiological, molecular biological and biochemical methods are based on 
standard techniques (Ausubel et al., 1994; Sambrock et al., 1989) or on the manufacturerʼs 
instructions. For all methods described, de-ionized sterile water, sterile solutions and sterile 
flasks were used. Unless otherwise mentioned, chemicals and reagents were obtained from 
Amersham-Pharmacia, Applied Biosystems, Biomol, Biorad, BostonBiochem, Difco, Fluka, 
Invitrogen, Kodak, Merck, New England Bioloabs, Promega, Roth, Roche, Riedel de Haen, 
Serva, or Sigma. 
 
 
6.1 Computational analysis 
 
For database searches (sequence search and comparison, literature research) electronic 
services provided by Saccharomyces Genome Database (http://www.yeastgenome.org/) and 
National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/) were used. DNA 
and protein sequence analyses (DNA restriction enzyme maps, DNA sequencing analyses, 
DNA primer design, protein sequence comparison) were done with the DNA-Star software 
(DNA Star Inc.). Western-Blot films were scanned on an AGFA T1200 and on a Mikrotek 
ScanMaker i900. For quantification of immunoblots, the chemiluminescence signals were 
detected by a CCD camera (LAS 3000, Fujifilm) and processed with Image Gauge V4.23 
(Fujifilm), and Adobe Photoshop (Adobe Systems Inc.). For the presentation of texts, tables, 
graphs and figures, the Microsoft Office software package (Microsoft Corp.) was used. 
 
 
6.2 Microbiological and genetic techniques 
 
6.2.1 E. coli techniques 
 
• E. coli strains used for cloning and protein expression 
- BL21 (DE3) E.coli B F- dcm ompT hsdS(rB-mB-) galλ (DE3) 
- BL21 Codon Plus (DE3) -RIL: E.coli B F- ompT hsdS(rB-mB-) dcm+ Tetr galλ (DE3) endA Hte 
[argU ileY leuW Camr] 
- XL1-Blue MR Δ(mcrA) Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 
lac 
 
• E. coli plasmids for protein expression 
Plasmids of the pET System from Novagen (pet28a/b/c(+)) and of the pGEX (pGEX4T1/2/3) 
from Amersham were used in this study. 
- pGEX4T1-ESS1 
- pGEX4T1-ESS1 WW 
- pGEX4T1-ESS1 Y23A 
- pGEX4T1-GST 
- pET28-Pin1 
- pET28-Pin1 mutant 
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• E. coli media  
LB-medium / (plates):         
1%  Trypton (Difco)  
0.5%  yeast extract (Difco)  
1%  NaCl  
(1.5%  agar) 
sterilized by autoclaving  
 
• Cultivation and storage of E. coli  
E. coli liquid cultures were grown in LB media at 37°C (or 22°C for protein expression 
experiments), with shaking at 200 rpm. Solid cultures were grown on LB agar plates at 37°C. 
Selection of transformed bacteria was done by supplementation of LB Medium or LB Plates 
with 50 µg/ml Ampicillin or 30 µg/ml Kanamycin. Density of liquid cultures was determined by 
measuring the absorbance at a wavelength of 600 nm (OD600) with a standard 
spectrophotometer (Eppendorf). Cultures on solid media were stored at 4°C up to 7 days. For 
long-term storage, stationary cultures were frozen in 15% (v/v) glycerol solutions at –80°C.  
 
• Preparation of chemically competent bacteria 
For the preparation of highly competent cells the method of Inoue et al. (1990) was followed, 
bacteria from frozen stock or single colonies from plates were used for inoculation of a 20 ml 
starter culture in SOB Medium (2% bacto-tryptone, 0.5% yeast extract, 0.05% NaCl and after 
components were dissolved addition of 1% 250 mM KCl, 5 N NaOH ad pH 7.0) and cultured 
for 4-6h 37°C shaking. Then three flasks with 500 ml of SOB Medium were inoculated with 1, 
2 and 5 ml of the starter culture and cultured overnight at 18°C. The cultures were chilled in 
ice-cold water after they reached an OD600 of 0.55 for 20 min. The cells were harvested by 
centrifugation (2500g, 10 min, 4°C) and the pellet resuspended in 100 ml pre-chilled Inoue 
Buffer (55 mM MnCl2, 15 mM CaCl2, 250 mM KCl, 10 mM PIPES pH 6.7) and again harvested 
by centrifugation. Cells were resuspended in 40 ml Inoue Buffer and 3 ml DMSO were added, 
the mixture was incubated on ice for 10 min. Aliquots of 100 µl were frozen in pre-chilled 
tubes in liquid nitrogen and afterwards stored at -80°C until use. 
 
• Transformation of plasmid DNA into bacteria cells 
Competent cells were thawn on ice and then mixed with 1-4 µl of dissolved plasmid DNA and 
incubated on ice for 30 min. A 42°C heat shock was performed for 1 min, followed by a 1 min 
incubation on ice. For recovery, 1 ml pre-warmed LB medium without antibiotics was added, 
and cells were incubated on a shaker (200 rpm) at 37°C for 1h. Transformed cells were 
selected by plating the cell suspension on antibiotic-containing LB agar plates and incubating 
the plates over-night at 37°C. 
 
• Isolation of plasmid DNA from E. coli 
Plasmid DNA was isolated by alkaline lysis and binding to an anion-exchange column using 
kits from Qiagen, Macherey&Nagel and Bioneer according to the manufacturerʼs protocol. 
DNA was quantified with a Nanodrop device (peqlab) with 1 OD250 = 50 µg DNA. 
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6.2.2 S. cerevisiae techniques 
 
• S. cerevisiae strains 
 
Name Relevant genotype Reference 
   
   
DF5 trp1-1 ura3-52 his3Δ200 leu2-3,11 lys2-801 Hoppe et al., 2000 
YDS109 ess1::HIS3MX, pESS1(ESS1 promoter)-ESS1: URA3 this study 
YDS066 ess1::HIS3MX, pESS1-ESS1-W15R this study 
YDS067 ess1::HIS3MX, pESS1-ESS1-H164R this study 
YDS124 rsp5::HIS3MX, pRSP5(RSP5 promoter)-RSP5:URA3 this study 
YDS119 DF5, pGAL1-10-mycSPT23HA::LEU2 this study 
YDS122 YDS066, pGAL1-10-mycSPT23HA::LEU2 this study 
YDS120 YDS067, pGAL1-10-mycSPT23HA::LEU2 this study 
YDS054 ess1::HIS3MX, pADH1-OLE1::LEU2 this study 
YDS113 DF5, mutated pOLE1-lacZ::LEU2 this study 
YDS114 DF5, pOLE1-lacZ::LEU2 this study 
YDS117 YDS066, mutated pOLE1-lacZ::LEU2 this study 
YDS118 YDS066, pOLE1-lacZ::LEU2 this study 
YDS115 YDS067, mutated pOLE1-lacZ::LEU2 this study 
YDS116 YDS067, pOLE1-lacZ::LEU2 this study 
DF5 pGAL1-10-mycSPT23HA::URA3  Hoppe et al., 2000 
DF5 spt23::HISG, mga2::LEU2, pMga2-MGA2:URA3 this study 
DF5 spt23::URA3 this study 
DF5 spt23::NAT this study 
YDS161 YDS066, pGAL1-10-mycSPT23HA::URA3 this study 
YDS160 YDS067, pGAL1-10-mycSPT23HA::URA3 this study 
YDS409• EY0986, CKA1-GFP::HIS3MX Huh et al., 2003 
YDS410• EY0986, CKA2-GFP::HIS3MX Huh et al., 2003 
YDS411• EY0986, CKB1-GFP::HIS3MX Huh et al., 2003 
YDS408• EY0986, CKB2-GFP::HIS3MX Huh et al., 2003 
 
All strains are isogenic to DF5 apart from the following exceptions: 
• These strains are based on the S288C derivative strain EY0986, obtained from Invitrogen. 
 
 
• S. cerevisiae vectors 
The following vectors were used in this study: 
- Centromeric plasmids (CEN): pYCplac33, pYCplac22, pYCplac111, pUG36 (URA3, CEN, 
MET25 promoter) (Niedenthal et al., 1996), pRS416 (Sirkorski and Hieter, 1989). 
- Highcopy 2µ plasmids: pYEplac195, pYEplac112, pYEplac181 
- Integrative plasmids: pYIplac211, pYIplac204, pYIplac128 (Gietz and Sugino, 1988) 
- Yeast-Two-Hybrid vectors: pGBT9, pGAD424 (Bartel et al., 1993), pGAD-C1-3, pGBD-C1-3 
(James et al., 1996) 
- Integrative plamids suitable for lacZ fusions: Yip356, Yip357, Yip367 (Kinney and Lusty, 
1986). 
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• S. cerevisiae plasmids 
ESS1 including its promoter and terminator was cloned (YCplac22, YCPlac33, YCplac111; 
with different markers), and the ess1-W15R, ess1-H164R, ess1-Y23A mutants were 
generated by site-directed mutagenesis. For overexpression, the corresponding DNA was 
cloned into YCplac22 under the control of the pGAL1-10 promoter, or for the competitive two-
hybrid assay, the pADH1 promoter. For fluorescence analysis of GFP-tagged ESS1, ESS1-
WW, ESS1-PPiase and mutants, the corresponding DNA was subcloned into pUG36 under 
the control of the pMET25 promoter. For two-hybrid analysis, ESS1 and ess1-WW were 
cloned into the pGAD vector. To construct GST-Ess1 and Gst-Ess1Y23A, Ess1 sequences 
corresponding to the full-length proteins were subcloned into pGEX4T-1 (GST) for expression 
in bacteria. mycSPT23HA under the control of its own promoter and terminator was subcloned 
to YCplac22 and used to generate the Spt23 SP mutants used in this study by site-directed 
mutagenesis. mycSPT23HA was subcloned into pUG36ΔGFP and expressed under the control 
of the pMET25 promoter. His6- and HA-epitope tagged ubiquitin were described previously 
and subcloned into YEplac195, YEplac181 and YEplac112 either under the control of the 
pMET25 or pADH1 promoter. For Ole1 transactivation assays, the corresponding wild-type or 
mutated Ole1 promoter was subcloned into Yip356, Yip357 or Yip367, the pGAL1-10 
promoter was subloned upstream of lacZ into YIplac211. 
 
• S. cerevisiae media & solutions 
- YPD / YPGal [plates]:  
1% (10 g/l) yeast extract (Difco) 
2% (20 g/l) bacto-peptone (Difco) 
2% (20 g/l) D-(+)-glucose or galactose 
[2% (20 g/l)  agar] 
sterilized by autoclaving  
 
- YPD G418/NAT [plates]: After autoclaving, YPD medium with 2% agar was cooled to 
50°C, and G418 (geneticine disulphate; Sigma) to 200 mg/l or NAT (nourseothricin, HKI Jena) 
to 100mg/l was added. 
 
- SC-media [plates]:  
0.67% (6.7 g/l) yeast nitrogen base (Difco) 
0.2% (2 g/l)  drop out amino acid mix (according to the requirements) 
2% (20 g/l) carbon source (glucose, raffinose, or galactose) 
[2% (20 g/l) agar]  
 
- SC 5-FOA [plates]:  
0.67% (6.7 g/l) yeast nitrogen base (Difco) 
0.2% (2 g/l)  drop out amino acid mix (according to the requirements) 
3% (30 g/l) adenine  
3% (30 g/l) uracil  
2% (20 g/l) glucose  
2% (20 g/l) agar  
After autoclaving, the mixture was cooled to 50°C, and 5'FOA was added to the final 
concentration of 1 g/l. 
 
- OA supplemented plates, oleic acid containing plates: After autoclaving, YPD or SC-medium 
with 2% agar was cooled to 50°C, and a premixed of oleic acid (Sigma) and NP40 (Fluka) 
was added in equal amounts with a final concentration of 0.2% (v/v).  
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• S. cerevisiae cultivation and storage 
Unless otherwise mentioned liquid cultures were incolulated with single yeast colonies from 
freshly streaked plates and grown overnight. In principle, the main culture was inoculated with 
a starter culture at a dilution of 1:100 – 1:1000 and grown until the culture reached the mid-log 
phase growth (1-3x107 cells/ml). Liquid cultures were grown at 30°C (temperature sensitive 
strains at 23°C), in an incubator with shaking at 150 - 250 rpm. Density of liquid cultures was 
determined by measuring the absorbance at a wavelength of OD600 with a standard 
spectrophotometer (Eppendorf).  Cultures on solid media were stored at 4°C up to 1 - 2 
months. For long-term storage, stationary cultures were frozen in 15% (v/v) glycerol solutions 
at –80°C. 
 
• Preparation and transformation of competent S. cerevisiae 
Preparation of competent yeast cells and transformation was based on standard protocols 
described in Knop et al. (1999). 
 
• Genomic integration by homologous recombination 
Chromosomal gene deletions or insertions of epitope tags were performed by a PCR strategy 
according to Knop et al. (1999) and Longtine et al. (1998). 
 
• Analyses of protein-protein interactions with the Two-Hybrid System  
The two proteins of interest for interaction were fused in frame to the DNA-binding and, 
respectively, the activation domain of the Gal4 transcription factor. The expression constructs 
of the fusion proteins were transformed in PJ69-7A cells (James et al., 1996). An interaction 
between the two proteins results in the reconstitution of the Gal4 transcription activator. 
Hence, the expression of reporter genes under the control of Gal4 (i.e. HIS3, ADE2) is turned 
on, and cells can grow on the respective selection media. 
Competitive protein-protein interactions were established in a Yeast-Three-Hybrid approach. 
In addtion to the Yeast-Two-Hybrid System, a third protein was cloned in frame under the 
control of the pADH1 promoter as a competitor and transformed in PJ69-7A Yeast-Two-
Hybrid strain created before (see above), as a control an empty plasmid with the ADH1 
promoter was transformed. 
 
• Phenotype analyses by growth tests  
Characterization of the yeast growth phenotype is based on the comparison of growth rates 
upon various conditions (e.g. different temperature or presence/absence of 18:1) of different 
yeast strains cells spotted in equal amounts on a solid medium. Yeast cultures grown to mid-
log growth phase or collected from fresh plates were diluted with sterile water to an OD600 of 
0.2, serial dilutions were prepared in the 96-well microtiter plate (1:5 or 1:10). 5 µl of each 
cells suspension were spotted on respective plates with a pin-stamp (48 or 96) and the plates 
were incubated at different temperatures. 
Moreover, this method allows the characterization of mutants of an essential gene, which are 
otherwise unable to support viability. In this case, cells expressing the wild-type gene only 
from a centromeric plasmids with the URA3 auxotrophy marker were transformed with 
different mutant alleles, either ts-allels or binding-mutants and plated on 5-FOA-containing 
plates. This drug counter-selects the URA3-expressing plasmids, and cells can survive only if 
the mutant alleles can confer viability.  
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6.3 Tissue culture methods 
 
• Cell lines 
U2-OS, human osteosarcoma, chromosomally highly altered, with chromosome counts in the 
hyper-triploid range. 
 
• Mammalian expression vectors 
- pcDNA3.1/GeneStorm (Invitrogen) 
- pcMV-Tag2/3/4 (Stratagene) 
 
• Plasmids for protein expression in mammalian cells 
HIS6- and HA-epitope tagged ubiquitin were described previously (Treier et al., 1994). Pin1 wt 
and Pin1 mutant were a gift from Prof. O. Stemmann. 
 
• Cultivation and storage of mammalian cells 
U2-OS cells were maintained and propagated at 37°C, 7.5% CO2 in DMEM (SIGMA) 
supplemented with 10% FCS. For long term storage, cell cultures were frozen in liquid 
nitrogen as follows,  cells were grown to a confluence of 80%, trypsinized, centrifuged and 
resuspended in 10% DMSO in fetal bovine serum. The cell suspension was distributed in 
cryo-vials (Nalgene) and transferred to pre-cooled isopropanol-filled cryo-containers 
(Nalgene) and frozen at –80°C. After two days, the cryo-vials were transferred to liquid 
nitrogen. 
 
• Transfection of mammalian cells 
Transient transfection of U2-OS cells was perfomed by electroporation using the Nucleofector 
kit according to the manufacturerʼs protocol (Amaxa). 
 
• Immunofluorescence microscopy 
Immunofluorescence was perfomed according to standard protocols after fixation in 3.7% 
paraformaldehyde (PFA). Images were acquired on a Leica DM RXA microscope equipped 
with a Hamatsu ORCA-ER digital camera, image acquisition was carried out using Openlab 
software. 
 
 
6.4 Molecular biology methods 
 
• Enzymatic manipulation of DNA 
Restriction enzymes were employed for sequence-specific cleavage of DNA according to 
standard protocols (Sambrock et al., 1989) and the instructions of the manufacturer (New 
England Biolabs). For the digestion of 1-5 µg 2-10 units of restriction enzyme were usually 
used. Reaction samples were incubated at the recommended temperature for 2 h. To avoid 
the re-circularization of linearized vectors, the 5' end of vector DNA was dephosphorylated by 
incubation with 5-10 units of Shrimp alkaline Phosphatase (NEB) at 37°C for 30 min. PCR 
products were digested overnight with 5-20 U of restriction enzyme. Digested DNA was 
subjected to gel electrophoresis, the bands were visualized by ethidium bromide staining, the 
favored DNA fragments were sliced out with a sterile razor blade and subsequently purified 
from the gel matrix using a standard extraction kit (Qiagen, Macherey&Nagel, Bioneer). 
 
• Ligation of DNA fragments 
Ligation of cohesive end DNA was carried out using T4 DNA Ligase (NEB) according to the 
manufacturerʼs instructions. Approximately 50-100 ng vector DNA were incubated with a 6-10 
fold molar excess of insert in a reaction volume of 20 µl. The samples were incubated 
overnight at 16°C and subsequently transformed into chemically competent cells.  
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• Separation of DNA fragments by gel electrophoresis 
Agarose gel electrophoresis was performed with Tris-borate buffered solutions (0.5-fold TBE: 
45 mM Tris-borate, 1 mM EDTA [pH 8.0]). DNA was mixed with loading buffer (5-fold 
concentrated: 25% glycerol, 0.25% SDS, 25 mM EDTA [pH 8.0], Orange G in H2O) and the 
mixtures transferred into the slots of the gel (0.8-1.6% agarose in TBE, mixed with 0.005% 
ethidium bromide after dissolution of the agarose). Electrophoresis was performed in minigels 
for 30-60 min at 5-15 V/cm.  
 
• DNA sequencing 
DNA sequencing was carried out by a modified Sanger dideoxy terminator cycle sequencing 
chemistry using the DYEnamic ET Terminator Cycle Sequencing Kit (Amersham) with 0.1 – 1 
μg DNA and 10 pmol primers, the ABI BigDye kit version 3.1, on a ABI 3730 48-capillary 
sequencer and 36 cm capillaries which was operated by the MPI of Biochemistry Core 
Facility.  
 
• Polymerase chain reaction (PCR) 
PCR was performed according to standard protocols. Amplification was performed using 
Phusion Polymerase (NEB), taq Polymerase or Vent DNA polymerases (NEB) in a total 
volume of 50 μl. Amplification was carried out with 25 cycles of melting (95°C for 30 s), 
annealing (55°C for 30 s) and amplification (temperature [68-72°C] and time was chosen 
according to the used polymerase [15-60 s per 1 kb of DNA]). 
 
• DNA site-directed mutagenesis 
The method used to generate point mutations, was a PCR-based strategy based on the 
QuickChange protocol (Stratagene). Two complementary oligonucleotide primers containing 
the mutated site in the middle, flanked by 15 bases of the target sequence overhang on each 
side were used. The melting temperature of the primer was calculated by Tm = 81.5 + 
[0.41(GC)] – [675/N] - [% of mismatch]. PCR amplification was performed using Phusion 
polymerase (NEB) in a total volume of 50 μl. Amplification was carried out with 20 cycles of 
melting (95°C for 15 s), annealing (Tm - 5°C for 30 s) and amplification (72°C for 20 s per 1 
kb of DNA). PCR products were subsequently digested with 10 U DpnI for 1-3 h, heat 
inactivated and transformed into bacteria.  
 
 
6.5 Protein biochemistry techniques 
 
• Measuring protein concentrations 
The Bradford assay (BioRad protein assay: BioRad) was used to determine protein 
concentrations. Concentrations were determined in an OD590 nm reading window of 0.1 to 2 
using standard spectrophotometers (Eppendorf).  
 
• SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
For the experiments presented in this study, proteins were resolved using a Bis-Tris-buffered 
gel system. 4-12% gradient Bis-Tris polyacrylamide gels were used, either bought from 
Invitrogen or self-poured using the Mighty Small gel system (Hoefer). Aequeos solutions of 
proteins or cell lysates were either mixed with 5-fold SDS sample buffer (312 mM Tris [pH 
6.8], 50% glycerol, 10% SDS, 25% ß-mercaptoethanol, 0.01% bromophenolblue) or HU 
sample buffer (8 M Urea, 5 % SDS, 1 mM  EDTA, 1.5 % DTT, 1 % Bromphenolblue, 
200  mM  Tris-HCl pH 6.8). Samples were boiled in SDS sample buffer (95°C, 5 min) or 
for 10 min in HU sample buffer and transferred to the slots of the gel. Precision Plus Protein 
All Blue Standards (BioRad) was used as a marker for relative molecular size of proteins. 
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• Immuoblot 
Proteins resolved by SDS-PAGE were transferred onto PVDF membranes (Millipore) using a 
tankblot device (Hoefer). Transfer was carried out in a cold room for 1.5 -  3 h in transfer 
buffer (25 mM Tris, 192 mM Glycin, 0.01% SDS and 20% methanol) with a constant voltage 
of 70 volt. The membrane was subsequently stained with Ponceau S if necessary, destained 
and washed with TBST (25 mM Tris [pH 7.5], 137 mM NaCl, 2.6 mM KCl, 0.05% Tween-20). 
The membrane was blocked afterwards using  2.5% w/v ECL AdvanceTM blocking reaent (GE 
Healthcare) in TBST (30 min, RT) on a rotating platform (50-100 rpm). 
Primary and secondary antibody were hybridized in 2.5 ECL AdvanceTM blocking 
reaent (GE Healthcare) in TBST overnight followed by extensive washing of the membrane 
with TBST (6 times, 10 min, RT). Secondary HRP-conjugated antibodies were applied in 
combination with chemi-luminiscence detection (ECL-Plus/ECL-Advanced Westernblot 
Detection Kit, GE Healthcare) on conventional films (Kodak) or LAS3000 CCD cameras (Fuji).  
 
• Immunoblot reprobing 
Membranes were stripped to reprobe by incubation in stripping buffer (63.5 mM Tris [pH 6.8], 
2% SDS, 100 mM DTT) for 45 min at 65°C.  
 
• ONPG Assay 
ONPG (o-nitrophenyl-beta-D-galacto-pyranoside) assay of beta-galactosidase activity in yeast 
was perfomed based on standard protocols described by Gietz et al. (1997). 
 
 
6.5.1 Preparation of cell lysates 
 
• Preparation of native yeast extracts 
Native protein extracts were employed in binding studies. Yeast cells of mid-log phase 
cultures were harvested by centrifugation and washed once with ice-cold PBS. Occasionally, 
cell pellets were frozen in liquid nitrogen and afterwards stored at –20°C. Pellets were 
resuspended in 250-500 µl lysis buffer (PBS, 0.125 mM MgCl2) supplemented with 1 mM 
PefaBloc (Roche), protease inhibitors (complete inhibitor set, Roche), and if needed 
phosphatase inhibitors (200 mM Na3VO4, 20 mM NaF, EDTA). After addition of zirkonia/silica 
beads (∅ 500 µm, ROTH) cells were lysed by vortexing 4-6 times for 2 min at 4°C, using a 
bead beater device (Retsch). The cell lysate was recovered by piggyback centrifugation after 
the bottom and the lid of the tube was perforated with a needle. Triton X-100 was added to 
the lysates (to a final concentration of 0.1-0.4%) to avoid unspecific binding. To extract 
integral membrane proteins (Spt23 p120) 0.2% dodecyl maltoside (Sigma) was added to the 
lysates and the lysate was incubated for 30 min at 4°C on a rotating wheel for solubilization.  
Cell debris was removed by centrifugation (770 g, 5 min, 4 °C). The whole cell extract 
contains the soluble fraction (cytosolic and nuclear proteins) as well as microsomes (ER, 
nuclear envelope and other organelles). The cytosolic fraction is partially contaminated with 
proteins from the lumen of organelles, which upon the lysis with zirconia/silica bead are 
partially disrupted. For separation of microsomes from the soluble phase, whole cell extracts 
were fractionated by high spin centrifugation (20000 g, 1 h, 4 °C). 
 
• Preparation of denatured yeast extracts & expression shut-off experiments 
Yeast cells were lysed under denaturing conditions in order to avoid de-conjugation of post-
translational modifications during lysis. Usually, mid-log phase growing cells from 1 ml of a 
yeast culture of 1 OD600 were harvested by centrifugation, resuspended in 1 ml ice-cold 
water and lysed by incubation with 150 µl 1.85 M NaOH/ 7.5% β-mercaptoethanol for 15 min 
on ice. Proteins were precipitated by addition of 150 µl 55% trichloroacetic acid (TCA) 
followed by incubation on ice for 10 min and centrifugation at 20000 g for 20 min at 4°C. The 
pellet was resuspended in 50 µl HU sample buffer. 
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Stability of mycSPT23HA expressed from the pGAL1-10 promoter was determined by 
cycloheximide chase after pGAL-promoter shut-off essentially as published (Richly et al., 
2005; Piwko et al., 2006). Stability of the mycSpt23HA SP mutants expressed from its own 
promoter was determined in a ∆spt23::URA3 background by cycloheximide chase (Richly et 
al., 2005; Piwko et al., 2006). 
 
• Preparation of native extracts from mammalian cells 
Lysates from U2-OS mammalian cells were prepared by either scraping cells from plates 
using a rubber policeman or by trypsination. Cells were then centrifuged (300 g, 3 min, RT) 
and washed once in PBS. Cells were resuspended in 100-200 µl of IP buffer (50 mM HEPES 
[pH 7.2], 150 mM NaCl, 2 mM EDTA, 0.8% Triton X-100) supplemented with 1 mM PefaBloc 
(Roche), complete protease inhibitors (Roche), 20 mM NaF, 200 mM Na3Vo4 phosphatase 
inhibitors, MG132 and additionally 1 mM NEM if ubiquitylation should be preserved. 
Suspensions were incubated on ice for 30 min. Cell debris was removed by centrifugation (10 
min, 16000g, 4°C). Hereafter an appropriate amount of the supernatant representing the cell 
lysate (input) was mixed with 2xSDS loading buffer.  
 
• TCA precipitation of proteins  
Proteins in solution were precipitated by addition of an equal volume of 10% TCA and 
incubation on ice for 10 min. Precipitated material was pelleted by centrifugation (16000 g, 
4°C, 10 min). Pellets were washed with acetone (-20°C), dried and resuspended in SDS 
loading buffer.  
 
 
6.5.2 Protein purification and binding experiments 
 
• Purification of recombinant protein from E. coli 
GST- as well as His6-fusion proteins were expressed in E. coli BL21(DE3)/RIL. E. coli 
cultures were inoculated and shaken at 37°C in LB with the appropriate antibiotic. Cells were 
harvested when OD600 reached 0.4, cultures were induced by adding 1 mM IPTG and further 
shaken overnight (RT). 
GST fusion proteins were purified as follows, cells from 1 l bacterial culture were 
resuspended in 30 ml E. coli lysis buffer (PBS containing, 0.125 mM MgCl2, complete 
protease inhibitors (Roche), Pefabloc (Roche), 0.5 mM DTT and 8% glycerol) and lysed by 
high pressure in an cell disruptor (Emulsiflex C5). For clearing, the lysate was incubated with 
Triton X-100 added to the final concentration of 1%, for 30 min at 4°C on a wheel, the lysate 
was subsequently centrifuged for 30 min at 20000g at 4°C. The supernatant was afterwards 
incubated with Gluthathion Sepharose (Amersham) for 3 h at 4°C. The column was washed 
with 25 column volumes GST washing buffer 1 (20 mM Tris [pH 7.5], 500 mM NaCl, 2 mM 
EDTA, 1% Triton-X-100, 1 mM DTT, 8% glycerol), 10 column volumes of GST washing buffer 
2 (PBS containing 0.125 mM MgCl2, 0.1% Triton-X-100, 0.5 mM DTT, 8% glycerol) and 10 
column volumes of GST washing buffer 3 (PBS containing 0.125 mM MgCl2, 1 mM DTT, 8% 
glycerol). Bound proteins were eluted with 5 column volumes GST elution buffer (PBS 
containing 10 mM glutathione, 8% glycerol), dialyzed against appropriate buffers, 
concentrated glycerol (10% end-concentration was added prior to freezing in liquid nitrogen.  
In the case of His6-fusion proteins, pellets were resuspended in NiNTA buffer (50 mM 
NaH2PO4 [pH 8.0], 300 mM NaCl, 20 mM imidazole, 2 mM PMSF, Complete protease 
inhibitors (Roche), 8% glycerol) and lysed by high pressure in an cell disruptor (Emulsiflex 
C5). Cleared lysates were applied to NiNTA agarose columns (Qiagen), columns washed with 
50 column volumes of NiNTA buffer and bound proteins eluted using 5 column volumes of 
NiNTA elution buffer (50 mM NaHPO [pH 8.0], 150 mM NaCl, 250 mM imidazole).  
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• Immunoprecipitation from native yeast extracts 
For immunoprecipitation experiments native yeast extracts were prepared and to 400-800 μl 
of cell lysate 20-40 μl of antibody-agarose slurry were added (for HA, myc). Coupled 
antibodies were incubated 2-4 h or overnight in cell lysates (4°C) on a rotating wheel 
Afterwards beads were washed five times with IP buffer including detergent and once without 
detergent, bound proteins were eluted by boiling the beads in HU sample buffer. 
 
• GST pull-down assay from native yeast extract 
For GST pull-down assays, 20 µg of GST or GST-fusion proteins in equal molar amounts 
were bound to GST Sepharose 1 h (4°C) in 200 µl lysis buffer, subsequently the beads were 
incubated with yeast native lysate for 2-4 h at 4 °C. Afterwards the beads were washed five 
times with the lysis buffer with detergent and once without detergent, bound proteins were 
eluted in HU sample buffer (10 min, 65°C).  
 
• NiNTA Chromatography from denatured yeast extracts 
Yeast cells transformed with His tagged ubiquitin expressed from the pADH1 or pMET25 
promoter were harvested and 200 OD600 cells were lysed in 5 ml 1.85 M NaOH / 7.5% β-
mercaptoethanol for 20 min on ice. The proteins were precipitated by addition of 5 ml 55% 
TCA and incubation for 20 min on ice. Subsequently, a centrifugation for 15 min at 3000g was 
performed, and the protein pellet was washed two times with ice-cold acetone to wash away 
all remaining TCA. The pellet was afterwards solubilized in buffer A (6 M guanidinium 
hydrochloride, 0.1 M NaH2PO4, 0.01 M Tris-HCl, 20 mM imidazole, pH 8) containing 0.05% 
Tween-20. Insoluble aggregates were removed by centrifugation for 30 min at 13000g and the 
protein solution was incubated overnight with 50 µl NiNTA Magnetic Agarose Beads (Qiagen). 
The beads were afterwards washed three times with buffer A containing 0.05% Tween-20, 
then four times with buffer C (8 M Urea, 0.1 M NaH2PO4, 0.01 M Tris-HCl, pH 6.3) with 0.05% 
Tween-20 and once with buffer C without Tween-20. Bound proteins were eluted by 
incubation with 30 µl 1% SDS at 65°C, dried in a SpeedVac (Eppendorf), solubilized in 10 µl 
water and 25 µl HU sample buffer (10 min, 65°C) and subjected to SDS-PAGE and 
immunoblotting  
 
• NiNTA Chromatography from denatured extracts of mammalian cells 
U2-OS cells were transiently transfected with either His or HA-tagged Ubiquitin (negative 
control) and harvested, pellets were washed once in PBS. Cells were lysed in 6 M guanidine-
HCl, 0.1 M NaH2PO4, 0.1% Tween 20, 0.01 M Tris [pH 8.0]. DNA was sheared by mild 
sonification (2 x 20 sec 20%). An aliquot of the lysate was kept for TCA precipitation (input). 
The remaining lysate was incubated with 20 µl magnetic NiNTA agarose beads 20 µl (Qiagen) 
for 3 - 5 h or overnight (RT). Beads were washed 5 times with 8 M urea, 0.1 M NaH2PO4, 
0.1% Tween 20, 0.01 M Tris [pH 8.0], twice with PBS, 0.01% Tween 20 and one with PBS. 
TCA precipitates (input) were washed twice with ice-cold acetone and boiled in loading buffer 
(2x), Bound proteins were eluted by boiling in loading buffer (2x) and subjected to SDS-PAGE 
and immunoblotting. 
 
• Antibodies 
The following antibodies were used: mouse monoclonal anti-p53 (DO-1, Santa Cruz), mouse 
monoclonal FK2 (MBL), mouse monoclonal anti-Pin1 (clone G8, Santa Cruz), mouse 
monoclonal anti-MEK-1 (H8, Santa Cruz), mouse monoclonal anti-CK2β (clone 6D5, Santa 
Cruz), mouse monoclonal anti-myc (clone 9E10, Santa Cruz), rabbit polyclonal anti-myc 
(clone A-14, Santa Cruz), mouse monoclonal anti-HA (clone F-7, Santa Cruz), mouse 
monoclonal anti-Dpm1 (5C5-A7, Molecular Probes), mouse monoclonal MPM2 (Upstate), 
mouse monoclonal anti-GST (Clone 3G10, GeneTex). 
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6.5.3 In vitro reactions 
 
• In vitro dephosphorylation assay 
In vitro dephosphorylation assays using recombinant λ-phosphatase (NEB) were perfomed on 
yeast native extracts with buffers omitting phosphatase inhibitors and immuopurified Spt23 
(from 100 – 200 OD600 culture) according to the manufacturerʼs protocol (NEB). 
 
• In vitro phosphorylation assay 
In vitro phosphorylation assays using recombinant CK2 (NEB) were perfomed on 
immuopurified Spt23 according to the manufacturerʼs protocol (NEB). The assay was either 
carried out hot with 32P-γ-ATP or cold with ATP. To preserve phosphorylation 20 mM NaF and 
200 mM Na3VO4 were added afterwards. 
 
• In vitro phosphorylation dependent pull-down assay 
Extracts (from 100 – 200 OD600 culture) of cells expressing mycSpt23HA under the control of 
the pGAL1-10 promoter were subjected to immunoprecipitation using anti-myc antibodies and 
incubated with or without λ-phosphatase. After phosphatase treatment, the washed samples 
were left untreated or phosphorylated in vitro with recombinant CK2 (NEB). These samples 
were finally assayed in GST pull-down experiments for binding to either recombinant GST-
Ess1 or GST alone (control). The unbound GST-Ess1 material (supernatant of the last 
experiment) was subjected to a GST pull-down to compare the amount of free to Spt23-bound 
GST-Ess1 material.  
 
• In vitro ubiquitylation 
In vitro ubiquitylation assays were performed as described previously (Li et al., 2003), 
however, with some modifications. For a standard reaction, 4.5 ng of recombinant His6-p53 
(p53) was mixed with the other purified recombinant components (Boston Biochem), these 
include E1 (20 ng), E2 (UbcH5c) (100 ng), E3 (His6-Mdm2) (4.5 to 202.5 ng) and 5 µg of 
ubiquitin, in 14 µl reaction buffer (50 mM HEPES pH 8.0, 50 mM NaCl, 0.5 mM DTT, 4 mM 
Mg-ATP, pH 8.0). Where indicated either GST (500 ng) or increasing amounts of Pin1 or a 
Pin1 mutant variant (Pin1mut) (0 - 351 ng) with single amino acid replacements in the WW 
and PPIase-domain were preincubated with p53 at 4°C for 1h before the other purified 
recombinant components were added. A lysine-less ubiquitin variant that fails to form 
polyubiquitin chains (UbK0) was used as a control for p53 polyubiquitylation. The 
ubiquitylation reactions were stopped after 60-120 min at 37°C by addition of loading buffer, 
and subsequently resolved by 4-12% gradient gels for western blot analysis. Polyubiquitylated 
p53 (poly-Ub) is detected by immunoblotting using an antibody specific for polyubiquitin 
conjugates (FK2), and oligoubiquitylated p53 (oligo-Ub) was detected by DO-1 antibody. 
 
References 
71 
7 References 
 
 
Amerik, A.Y., and Hochstrasser, M. (2004). Mechanism and function of deubiquitinating 
enzymes. Biochim Biophys Acta 1695, 189-207. 
 
Ayala, G., Wang, D., Wulf, G., Frolov, A., Li, R., Sowadski, J., Wheeler, T.M., Lu, K.P., and 
Bao, L. (2003). The prolyl isomerase Pin1 is a novel prognostic marker in human prostate 
cancer. Cancer Res 63, 6244-6251. 
 
Aza-Blanc, P., Ramírez-Weber, F.A., Laget, M.P., Schwartz, C., and Kornberg, T.B. (1997). 
Proteolysis that is inhibited by hedgehog targets Cubitus interruptus protein to the nucleus 
and converts it to a repressor. Cell 89, 1043-1053. 
 
Bedford, M.T., Chan, D.C., and Leder, P. (1997). FBP WW domains and the Abl SH3 domain 
bind to a specific class of proline-rich ligands. EMBO J 16, 2376-2383. 
 
Bedford, M.T., Reed, R., and Leder, P. (1998). WW domain-mediated interactions reveal a 
spliceosome-associated protein that binds a third class of proline-rich motif: the proline 
glycine and methionine-rich motif. Proc Natl Acad Sci USA 95, 10602-10607. 
 
Bedford, M.T., Sarbassova, D., Xu, J., Leder, P., and Yaffe, M.B. (2000). A novel pro-Arg 
motif recognized by WW domains. J Biol Chem 275, 10359-10369. 
 
Behrens, M.I., Lendon, C., and Roe, C.M. (2009). A common biological mechanism in cancer 
and Alzheimer's disease? Current Alzheimer research 6, 196-204. 
 
Blume-Jensen, P., and Hunter, T. (2001). Oncogenic kinase signalling. Nature 411, 355-365. 
 
Braun, S., Matuschewski, K., Rape, M., Thoms, S., and Jentsch, S. (2002). Role of the 
ubiquitin-selective CDC48(UFD1/NPL4 )chaperone (segregase) in ERAD of OLE1 and other 
substrates. EMBO J 21, 615-621. 
 
Brooks, C.L., and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell 21, 307-315. 
 
Brooks, C.L., Li, M., and Gu, W. (2007). Mechanistic studies of MDM2-mediated ubiquitination 
in p53 regulation. J Biol Chem 282, 22804-22815. 
 
Bulbarelli, A., Lonati, E., Cazzaniga, E., Gregori, M., and Masserini, M. (2009). Pin1 affects 
tau phosphorylation in response to Abeta oligomers. Mol Cell Neurosci. 
 
Chang, A., Cheang, S., Espanel, X., and Sudol, M. (2000). Rsp5 WW domains interact 
directly with the carboxyl-terminal domain of RNA polymerase II. J Biol Chem 275, 20562-
20571. 
 
Chen, Z.J. (2005). Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 7, 758-765. 
 
Chiu, Y., Zhao, M., and Chen, Z. (2009). Ubiquitin in NF-kappaB Signaling. Chem Rev. 
 
Ciechanover, A., Elias, S., Heller, H., and Hershko, A. (1982). "Covalent affinity" purification of 
ubiquitin-activating enzyme. J Biol Chem 257, 2537-2542. 
 
Clegg, H.V., Itahana, K., and Zhang, Y. (2008). Unlocking the Mdm2-p53 loop: ubiquitin is the 
key. Cell Cycle 7, 287-292. 
 
References 
72 
Cohen, S., Achbert-Weiner, H., and Ciechanover, A. (2004). Dual effects of IkappaB kinase 
beta-mediated phosphorylation on p105 Fate: SCF(beta-TrCP)-dependent degradation and 
SCF(beta-TrCP)-independent processing. Mol Cell Biol 24, 475-486. 
 
Cohen, S., Lahav-Baratz, S., and Ciechanover, A. (2006). Two distinct ubiquitin-dependent 
mechanisms are involved in NF-kappaB p105 proteolysis. Biochem Biophys Res Commun 
345, 7-13. 
 
Davis, F.M., Tsao, T.Y., Fowler, S.K., and Rao, P.N. (1983). Monoclonal antibodies to mitotic 
cells. Proc Natl Acad Sci USA 80, 2926-2930. 
 
Dawson, T.M., and Dawson, V.L. (2003). Rare genetic mutations shed light on the 
pathogenesis of Parkinson disease. J Clin Invest 111, 145-151. 
 
Dolinski, K., Muir, S., Cardenas, M., and Heitman, J. (1997). All cyclophilins and FK506 
binding proteins are, individually and collectively, dispensable for viability in Saccharomyces 
cerevisiae. Proc Natl Acad Sci USA 94, 13093-13098. 
 
Dupré, S., Urban-Grimal, D., and Haguenauer-Tsapis, R. (2004). Ubiquitin and endocytic 
internalization in yeast and animal cells. Biochim Biophys Acta 1695, 89-111. 
 
Fang, S., Jensen, J.P., Ludwig, R.L., Vousden, K.H., and Weissman, A.M. (2000). Mdm2 is a 
RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275, 8945-
8951. 
 
Fang, S., and Weissman, A.M. (2004). A field guide to ubiquitylation. Cell Mol Life Sci 61, 
1546-1561. 
 
Finn, G., and Lu, K.P. (2008). Phosphorylation-specific prolyl isomerase Pin1 as a new 
diagnostic and therapeutic target for cancer. Curr Cancer Drug Targets 8, 223-229. 
 
Galan, J.M., and Haguenauer-Tsapis, R. (1997). Ubiquitin lys63 is involved in ubiquitination of 
a yeast plasma membrane protein. EMBO J 16, 5847-5854. 
 
Glickman, M.H., and Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: 
destruction for the sake of construction. Physiol Rev 82, 373-428. 
 
Haas, A.L., Warms, J.V., Hershko, A., and Rose, I.A. (1982). Ubiquitin-activating enzyme. 
Mechanism and role in protein-ubiquitin conjugation. J Biol Chem 257, 2543-2548. 
 
Haas, A.L., Warms, J.V., and Rose, I.A. (1983). Ubiquitin adenylate: structure and role in 
ubiquitin activation. Biochemistry 22, 4388-4394. 
 
Hanes, S.D., Shank, P.R., and Bostian, K.A. (1989). Sequence and mutational analysis of 
ESS1, a gene essential for growth in Saccharomyces cerevisiae. Yeast 5, 55-72. 
 
Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation 
of p53. Nature 387, 296-299. 
 
Hennig, L., Christner, C., Kipping, M., Schelbert, B., Rücknagel, K.P., Grabley, S., Küllertz, 
G., and Fischer, G. (1998). Selective inactivation of parvulin-like peptidyl-prolyl cis/trans 
isomerases by juglone. Biochemistry 37, 5953-5960. 
 
Hershko, A., and Ciechanover, A. (1998). The ubiquitin system. Annu Rev Biochem 67, 425-
479. 
 
Hershko, A., Heller, H., Eytan, E., and Reiss, Y. (1986). The protein substrate binding site of 
the ubiquitin-protein ligase system. J Biol Chem 261, 11992-11999. 
References 
73 
Hoege, C., Pfander, B., Moldovan, G.-L., Pyrowolakis, G., and Jentsch, S. (2002). RAD6-
dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419, 
135-141. 
 
Honda, R., Tanaka, H., and Yasuda, H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for 
tumor suppressor p53. FEBS Lett 420, 25-27. 
 
Honda, R., and Yasuda, H. (2000). Activity of MDM2, a ubiquitin ligase, toward p53 or itself is 
dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476. 
 
Hoppe, T. (2005). Multiubiquitylation by E4 enzymes: 'one size' doesn't fit all. Trends Biochem 
Sci 30, 183-187. 
 
Hoppe, T., Matuschewski, K., Rape, M., Schlenker, S., Ulrich, H.D., and Jentsch, S. (2000). 
Activation of a membrane-bound transcription factor by regulated ubiquitin/proteasome-
dependent processing. Cell 102, 577-586. 
 
Hoppe, T., Rape, M., and Jentsch, S. (2001). Membrane-bound transcription factors: 
regulated release by RIP or RUP. Curr Opin Cell Biol 13, 344-348. 
 
Horák, J. (2003). The role of ubiquitin in down-regulation and intracellular sorting of 
membrane proteins: insights from yeast. Biochim Biophys Acta 1614, 139-155. 
 
Hunter, T. (1998). Prolyl isomerases and nuclear function. Cell 92, 141-143. 
 
Hutchins, J.R.A., and Clarke, P.R. (2004). Many fingers on the mitotic trigger: post-
translational regulation of the Cdc25C phosphatase. Cell Cycle 3, 41-45. 
 
Iakoucheva, L.M., Radivojac, P., Brown, C.J., O'Connor, T.R., Sikes, J.G., Obradovic, Z., and 
Dunker, A.K. (2004). The importance of intrinsic disorder for protein phosphorylation. Nucleic 
Acids Res 32, 1037-1049. 
 
Jentsch, S. (1992). Ubiquitin-dependent protein degradation: a cellular perspective. Trends 
Cell Biol 2, 98-103. 
 
Jentsch, S., and Rumpf, S. (2007). Cdc48 (p97): a "molecular gearbox" in the ubiquitin 
pathway? Trends Biochem Sci 32, 6-11. 
 
Jin, J., Li, X., Gygi, S.P., and Harper, J.W. (2007). Dual E1 activation systems for ubiquitin 
differentially regulate E2 enzyme charging. Nature 447, 1135-1138. 
 
Jin, L., Williamson, A., Banerjee, S., Philipp, I., and Rape, M. (2008). Mechanism of ubiquitin-
chain formation by the human anaphase-promoting complex. Cell 133, 653-665. 
 
Jones, S.N., Roe, A.E., Donehower, L.A., and Bradley, A. (1995). Rescue of embryonic 
lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208. 
 
Kaiser, P., and Fon, E.A. (2007). Expanding horizons at Big Sky. Symposium on ubiquitin and 
signaling. EMBO Rep 8, 817-822. 
 
Kerscher, O., Felberbaum, R., and Hochstrasser, M. (2006). Modification of proteins by 
ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22, 159-180. 
 
Kim, C.-J., Cho, Y.-G., Park, Y.-G., Nam, S.-W., Kim, S.-Y., Lee, S.-H., Yoo, N.-J., Lee, J.-Y., 
and Park, W.-S. (2005). Pin1 overexpression in colorectal cancer and its correlation with 
aberrant beta-catenin expression. World J Gastroenterol 11, 5006-5009. 
 
References 
74 
Kirisako, T., Kamei, K., Murata, S., Kato, M., Fukumoto, H., Kanie, M., Sano, S., Tokunaga, 
F., Tanaka, K., and Iwai, K. (2006). A ubiquitin ligase complex assembles linear polyubiquitin 
chains. EMBO J 25, 4877-4887. 
 
Koegl, M., Hoppe, T., Schlenker, S., Ulrich, H.D., Mayer, T.U., and Jentsch, S. (1999). A 
novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96, 635-644. 
 
Kops, O., Zhou, X.Z., and Lu, K.P. (2002). Pin1 modulates the dephosphorylation of the RNA 
polymerase II C-terminal domain by yeast Fcp1. FEBS Lett 513, 305-311. 
 
Kravtsova-Ivantsiv, Y., Cohen, S., and Ciechanover, A. (2009). Modification by single ubiquitin 
moieties rather than polyubiquitination is sufficient for proteasomal processing of the p105 
NF-kappaB precursor. Mol Cell 33, 496-504. 
 
Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by Mdm2. 
Nature 387, 299-303. 
 
Lai, Z., Ferry, K.V., Diamond, M.A., Wee, K.E., Kim, Y.B., Ma, J., Yang, T., Benfield, P.A., 
Copeland, R.A., and Auger, K.R. (2001). Human mdm2 mediates multiple mono-ubiquitination 
of p53 by a mechanism requiring enzyme isomerization. J Biol Chem 276, 31357-31367. 
 
Lane, D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15-16. 
 
Lee, T.H., Tun-Kyi, A., Shi, R., Lim, J., Soohoo, C., Finn, G., Balastik, M., Pastorino, L., Wulf, 
G., Zhou, X.Z., et al. (2009). Essential role of Pin1 in the regulation of TRF1 stability and 
telomere maintenance. Nat Cell Biol 11, 97-105. 
 
Levine, A.J. (1992). The p53 tumor-suppressor gene. N Engl J Med 326, 1350-1352. 
 
Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331. 
 
Li, M., Brooks, C.L., Wu-Baer, F., Chen, D., Baer, R., and Gu, W. (2003). Mono- versus 
polyubiquitination: differential control of p53 fate by Mdm2. Science 302, 1972-1975. 
 
Liao, Y., Wei, Y., Zhou, X., Yang, J., Dai, C., Chen, Y., Agarwal, N., Sarbassov, D., Shi, D., 
Yu, D., et al. (2009). Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of 
PKB/Akt stability and activation phosphorylation. Oncogene. 
 
Lim, J., Balastik, M., Lee, T.H., Nakamura, K., Liou, Y.-C., Sun, A., Finn, G., Pastorino, L., 
Lee, V.M.-Y., and Lu, K.P. (2008). Pin1 has opposite effects on wild-type and P301L tau 
stability and tauopathy. J Clin Invest 118, 1877-1889. 
 
Lin, L., DeMartino, G.N., and Greene, W.C. (2000). Cotranslational dimerization of the Rel 
homology domain of NF-kappaB1 generates p50-p105 heterodimers and is required for 
effective p50 production. EMBO J 19, 4712-4722. 
 
Liu, Y.-C. (2004). Ubiquitin ligases and the immune response. Annu Rev Immunol 22, 81-127. 
 
Ljungman, M. (2000). Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. 
Neoplasia 2, 208-225. 
 
Lu, K.P. (2004). Pinning down cell signaling, cancer and Alzheimer's disease. Trends 
Biochem Sci 29, 200-209. 
 
Lu, K.P., Finn, G., Lee, T.H., and Nicholson, L.K. (2007). Prolyl cis-trans isomerization as a 
molecular timer. Nat Chem Biol 3, 619-629. 
 
References 
75 
Lu, K.P., Hanes, S.D., and Hunter, T. (1996). A human peptidyl-prolyl isomerase essential for 
regulation of mitosis. Nature 380, 544-547. 
 
Lu, K.P., Liou, Y.C., and Zhou, X.Z. (2002). Pinning down proline-directed phosphorylation 
signaling. Trends Cell Biol 12, 164-172. 
 
Lu, K.P., and Zhou, X.Z. (2007). The prolyl isomerase PIN1: a pivotal new twist in 
phosphorylation signalling and disease. Nat Rev Mol Cell Biol 8, 904-916. 
 
Lu, P.-J., Zhou, X.Z., Liou, Y.-C., Noel, J.P., and Lu, K.P. (2002). Critical role of WW domain 
phosphorylation in regulating phosphoserine binding activity and Pin1 function. J Biol Chem 
277, 2381-2384. 
 
Lu, P.J., Zhou, X.Z., Shen, M., and Lu, K.P. (1999). Function of WW domains as 
phosphoserine- or phosphothreonine-binding modules. Science 283, 1325-1328. 
 
Mantovani, F., Gostissa, M., Collavin, L., and Del Sal, G. (2004). KeePin' the p53 family in 
good shape. Cell Cycle 3, 905-911. 
 
Matiuhin, Y., Kirkpatrick, D.S., Ziv, I., Kim, W., Dakshinamurthy, A., Kleifeld, O., Gygi, S.P., 
Reis, N., and Glickman, M.H. (2008). Extraproteasomal Rpn10 restricts access of the 
polyubiquitin-binding protein Dsk2 to proteasome. Mol Cell 32, 415-425. 
 
Meek, D.W. (2004). The p53 response to DNA damage. DNA Repair (Amst) 3, 1049-1056. 
 
Miranda, M., and Sorkin, A. (2007). Regulation of receptors and transporters by ubiquitination: 
new insights into surprisingly similar mechanisms. Mol Interv 7, 157-167. 
 
Momand, J., Zambetti, G.P., Olson, D.C., George, D., and Levine, A.J. (1992). The mdm-2 
oncogene product forms a complex with the p53 protein and inhibits p53-mediated 
transactivation. Cell 69, 1237-1245. 
 
Montes de Oca Luna, R., Wagner, D.S., and Lozano, G. (1995). Rescue of early embryonic 
lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206. 
 
Morris, D.P., Phatnani, H.P., and Greenleaf, A.L. (1999). Phospho-carboxyl-terminal domain 
binding and the role of a prolyl isomerase in pre-mRNA 3'-End formation. J Biol Chem 274, 
31583-31587. 
 
Nakayama, K.I., and Nakayama, K. (2006). Ubiquitin ligases: cell-cycle control and cancer. 
Nat Rev Cancer 6, 369-381. 
 
Newton, K., Matsumoto, M.L., Wertz, I.E., Kirkpatrick, D.S., Lill, J.R., Tan, J., Dugger, D., 
Gordon, N., Sidhu, S.S., Fellouse, F.A., et al. (2008). Ubiquitin chain editing revealed by 
polyubiquitin linkage-specific antibodies. Cell 134, 668-678. 
 
Okamoto, K., Taya, Y., and Nakagama, H. (2009). Mdmx enhances p53 ubiquitination by 
altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett. 
 
Palombella, V.J., Rando, O.J., Goldberg, A.L., and Maniatis, T. (1994). The ubiquitin-
proteasome pathway is required for processing the NF-kappa B1 precursor protein and the 
activation of NF-kappa B. Cell 78, 773-785. 
 
Paulsen, M.T., and Ljungman, M. (2005). The natural toxin juglone causes degradation of p53 
and induces rapid H2AX phosphorylation and cell death in human fibroblasts. Toxicol Appl 
Pharmacol 209, 1-9. 
 
References 
76 
Pawson, T., and Scott, J.D. (2005). Protein phosphorylation in signaling--50 years and 
counting. Trends Biochem Sci 30, 286-290. 
 
Pelzer, C., Kassner, I., Matentzoglu, K., Singh, R.K., Wollscheid, H.-P., Scheffner, M., 
Schmidtke, G., and Groettrup, M. (2007). UBE1L2, a novel E1 enzyme specific for ubiquitin. J 
Biol Chem 282, 23010-23014. 
 
Peng, J., Schwartz, D., Elias, J.E., Thoreen, C.C., Cheng, D., Marsischky, G., Roelofs, J., 
Finley, D., and Gygi, S.P. (2003). A proteomics approach to understanding protein 
ubiquitination. Nat Biotechnol 21, 921-926. 
 
Pickart, C.M. (2000). Ubiquitin in chains. Trends Biochem Sci 25, 544-548. 
 
Pickart, C.M. (2001). Mechanisms underlying ubiquitination. Annu Rev Biochem 70, 503-533. 
 
Pickart, C.M., and Fushman, D. (2004). Polyubiquitin chains: polymeric protein signals. 
Current opinion in chemical biology 8, 610-616. 
 
Pickart, C.M., and Rose, I.A. (1985). Ubiquitin carboxyl-terminal hydrolase acts on ubiquitin 
carboxyl-terminal amides. J Biol Chem 260, 7903-7910. 
 
Piwko, W., and Jentsch, S. (2006). Proteasome-mediated protein processing by bidirectional 
degradation initiated from an internal site. Nat Struct Mol Biol 13, 691-697. 
 
Prakash, S., Tian, L., Ratliff, K.S., Lehotzky, R.E., and Matouschek, A. (2004). An 
unstructured initiation site is required for efficient proteasome-mediated degradation. Nat 
Struct Mol Biol 11, 830-837. 
 
Ranganathan, R., Lu, K.P., Hunter, T., and Noel, J.P. (1997). Structural and functional 
analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation 
dependent. Cell 89, 875-886. 
 
Rape, M., Hoppe, T., Gorr, I., Kalocay, M., Richly, H., and Jentsch, S. (2001). Mobilization of 
processed, membrane-tethered SPT23 transcription factor by CDC48(UFD1/NPL4), a 
ubiquitin-selective chaperone. Cell 107, 667-677. 
 
Richly, H., Rape, M., Braun, S., Rumpf, S., Hoege, C., and Jentsch, S. (2005). A series of 
ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and 
proteasomal targeting. Cell 120, 73-84. 
 
Rippmann, J.F., Hobbie, S., Daiber, C., Guilliard, B., Bauer, M., Birk, J., Nar, H., Garin-Chesa, 
P., Rettig, W.J., and Schnapp, A. (2000). Phosphorylation-dependent proline isomerization 
catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis. Cell Growth Differ 
11, 409-416. 
 
Rodrigo-Brenni, M.C., and Morgan, D.O. (2007). Sequential E2s drive polyubiquitin chain 
assembly on APC targets. Cell 130, 127-139. 
 
Rodriguez, M.S., Gwizdek, C., Haguenauer-Tsapis, R., and Dargemont, C. (2003). The HECT 
ubiquitin ligase Rsp5p is required for proper nuclear export of mRNA in Saccharomyces 
cerevisiae. Traffic 4, 566-575. 
 
Rose, I.A., and Warms, J.V. (1983). An enzyme with ubiquitin carboxy-terminal esterase 
activity from reticulocytes. Biochemistry 22, 4234-4237. 
 
Rothwarf, D.M., and Karin, M. (1999). The NF-kappa B activation pathway: a paradigm in 
information transfer from membrane to nucleus. Sci STKE 1999, RE1. 
 
References 
77 
Rotin, D. (1998). WW (WWP) domains: from structure to function. Curr Top Microbiol Immunol 
228, 115-133. 
 
Rumpf, S., and Jentsch, S. (2006). Functional division of substrate processing cofactors of the 
ubiquitin-selective Cdc48 chaperone. Mol Cell 21, 261-269. 
 
Ryan, K.M., and Vousden, K.H. (2002). Cancer: pinning a change on p53. Nature 419, 795, 
797. 
 
Ryo, A., Liou, Y.-C., Lu, K.P., and Wulf, G. (2003). Prolyl isomerase Pin1: a catalyst for 
oncogenesis and a potential therapeutic target in cancer. J Cell Sci 116, 773-783. 
 
Ryo, A., Nakamura, M., Wulf, G., Liou, Y.C., and Lu, K.P. (2001). Pin1 regulates turnover and 
subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol 3, 
793-801. 
 
Ryo, A., Suizu, F., Yoshida, Y., Perrem, K., Liou, Y.-C., Wulf, G., Rottapel, R., Yamaoka, S., 
and Lu, K.P. (2003). Regulation of NF-kappaB signaling by Pin1-dependent prolyl 
isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 12, 1413-1426. 
 
Ryo, A., Wulf, G., Lee, T.H., and Lu, K.P. (2009). Pinning down HER2-ER crosstalk in SMRT 
regulation. Trends Biochem Sci 34, 162-165. 
 
Saeki, Y., Tayama, Y., Toh-e, A., and Yokosawa, H. (2004). Definitive evidence for Ufd2-
catalyzed elongation of the ubiquitin chain through Lys48 linkage. Biochem Biophys Res 
Commun 320, 840-845. 
 
Sasaki, H., Nishizaki, Y., Hui, C., Nakafuku, M., and Kondoh, H. (1999). Regulation of Gli2 
and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as 
primary mediators of Shh signaling. Development 126, 3915-3924. 
 
Scheffner, M., Huibregtse, J.M., Vierstra, R.D., and Howley, P.M. (1993). The HPV-16 E6 and 
E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 
495-505. 
 
Scheffner, M., and Staub, O. (2007). HECT E3s and human disease. BMC Biochem 8 Suppl 
1, S6. 
 
Schwarz, S.E., Rosa, J.L., and Scheffner, M. (1998). Characterization of human hect domain 
family members and their interaction with UbcH5 and UbcH7. J Biol Chem 273, 12148-12154. 
 
Searle, J.S., Schollaert, K.L., Wilkins, B.J., and Sanchez, Y. (2004). The DNA damage 
checkpoint and PKA pathways converge on APC substrates and Cdc20 to regulate mitotic 
progression. Nat Cell Biol 6, 138-145. 
 
Shaw, P.E. (2007). Peptidyl-prolyl cis/trans isomerases and transcription: is there a twist in 
the tail? EMBO Rep 8, 40-45. 
 
Shcherbik, N., Kee, Y., Lyon, N., Huibregtse, J.M., and Haines, D.S. (2004). A single PXY 
motif located within the carboxyl terminus of Spt23p and Mga2p mediates a physical and 
functional interaction with ubiquitin ligase Rsp5p. J Biol Chem 279, 53892-53898. 
 
Shi, D., Pop, M.S., Kulikov, R., Love, I.M., Kung, A.L., and Grossman, S.R. (2009). CBP and 
p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci USA 106, 16275-
16280. 
 
Soussi, T., and Béroud, C. (2001). Assessing TP53 status in human tumours to evaluate 
clinical outcome. Nat Rev Cancer 1, 233-240. 
References 
78 
Staub, O., and Rotin, D. (1996). WW domains. Structure 4, 495-499. 
 
Staub, O., and Rotin, D. (2006). Role of ubiquitylation in cellular membrane transport. Physiol 
Rev 86, 669-707. 
 
Sudol, M. (1996). Structure and function of the WW domain. Prog Biophys Mol Biol 65, 113-
132. 
 
Sudol, M., Chen, H.I., Bougeret, C., Einbond, A., and Bork, P. (1995). Characterization of a 
novel protein-binding module--the WW domain. FEBS Lett 369, 67-71. 
 
Sudol, M., and Hunter, T. (2000). NeW wrinkles for an old domain. Cell 103, 1001-1004. 
 
Tagwerker, C., Flick, K., Cui, M., Guerrero, C., Dou, Y., Auer, B., Baldi, P., Huang, L., and 
Kaiser, P. (2006). A tandem affinity tag for two-step purification under fully denaturing 
conditions: application in ubiquitin profiling and protein complex identification combined with in 
vivocross-linking. Mol Cell Proteomics 5, 737-748. 
 
Takahashi, K., Uchida, C., Shin, R.-W., Shimazaki, K., and Uchida, T. (2008). Prolyl 
isomerase, Pin1: new findings of post-translational modifications and physiological substrates 
in cancer, asthma and Alzheimer's disease. Cell Mol Life Sci 65, 359-375. 
 
Thrower, J.S., Hoffman, L., Rechsteiner, M., and Pickart, C.M. (2000). Recognition of the 
polyubiquitin proteolytic signal. EMBO J 19, 94-102. 
 
Tian, L., Holmgren, R.A., and Matouschek, A. (2005). A conserved processing mechanism 
regulates the activity of transcription factors Cubitus interruptus and NF-kappaB. Nat Struct 
Mol Biol 12, 1045-1053. 
 
Tokunaga, F., Sakata, S.-i., Saeki, Y., Satomi, Y., Kirisako, T., Kamei, K., Nakagawa, T., 
Kato, M., Murata, S., Yamaoka, S., et al. (2009). Involvement of linear polyubiquitylation of 
NEMO in NF-kappaB activation. Nat Cell Biol 11, 123-132. 
 
Travers, K.J., Patil, C.K., Wodicka, L., Lockhart, D.J., Weissman, J.S., and Walter, P. (2000). 
Functional and genomic analyses reveal an essential coordination between the unfolded 
protein response and ER-associated degradation. Cell 101, 249-258. 
 
Vousden, K.H. (2002). Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 
1602, 47-59. 
 
Welchman, R.L., Gordon, C., and Mayer, R.J. (2005). Ubiquitin and ubiquitin-like proteins as 
multifunctional signals. Nat Rev Mol Cell Biol 6, 599-609. 
 
Willems, A.R., Schwab, M., and Tyers, M. (2004). A hitchhiker's guide to the cullin ubiquitin 
ligases: SCF and its kin. Biochim Biophys Acta 1695, 133-170. 
 
Wu, X., Chang, A., Sudol, M., and Hanes, S.D. (2001). Genetic interactions between the 
ESS1 prolyl-isomerase and the RSP5 ubiquitin ligase reveal opposing effects on RNA 
polymerase II function. Curr Genet 40, 234-242. 
 
Wu, X., Wilcox, C.B., Devasahayam, G., Hackett, R.L., Arévalo-Rodríguez, M., Cardenas, 
M.E., Heitman, J., and Hanes, S.D. (2000). The Ess1 prolyl isomerase is linked to chromatin 
remodeling complexes and the general transcription machinery. EMBO J 19, 3727-3738. 
 
Wulf, G., Finn, G., Suizu, F., and Lu, K.P. (2005). Phosphorylation-specific prolyl 
isomerization: is there an underlying theme? Nat Cell Biol 7, 435-441. 
 
References 
79 
Wulf, G., Garg, P., Liou, Y.-C., Iglehart, D., and Lu, K.P. (2004). Modeling breast cancer in 
vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J 23, 3397-3407. 
 
Wulf, G.M., Liou, Y.-C., Ryo, A., Lee, S.W., and Lu, K.P. (2002). Role of Pin1 in the regulation 
of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA 
damage. J Biol Chem 277, 47976-47979. 
 
Xirodimas, D.P., Stephen, C.W., and Lane, D.P. (2001). Cocompartmentalization of p53 and 
Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res 270, 66-
77. 
 
Xu, P., and Peng, J. (2006). Dissecting the ubiquitin pathway by mass spectrometry. Biochim 
Biophys Acta 1764, 1940-1947. 
 
Yaffe, M.B. (2002). How do 14-3-3 proteins work?-- Gatekeeper phosphorylation and the 
molecular anvil hypothesis. FEBS Lett 513, 53-57. 
 
Yaffe, M.B. (2002). Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell 
Biol 3, 177-186. 
 
Yaffe, M.B., Schutkowski, M., Shen, M., Zhou, X.Z., Stukenberg, P.T., Rahfeld, J.U., Xu, J., 
Kuang, J., Kirschner, M.W., Fischer, G., et al. (1997). Sequence-specific and 
phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. 
Science 278, 1957-1960. 
 
Yu, Z.K., Geyer, R.K., and Maki, C.G. (2000). MDM2-dependent ubiquitination of nuclear and 
cytoplasmic P53. Oncogene 19, 5892-5897. 
 
Zacchi, P., Gostissa, M., Uchida, T., Salvagno, C., Avolio, F., Volinia, S., Ronai, Z.e., 
Blandino, G., Schneider, C., and Del Sal, G. (2002). The prolyl isomerase Pin1 reveals a 
mechanism to control p53 functions after genotoxic insults. Nature 419, 853-857. 
 
Zhang, S., Burkett, T.J., Yamashita, I., and Garfinkel, D.J. (1997). Genetic redundancy 
between SPT23 and MGA2: regulators of Ty-induced mutations and Ty1 transcription in 
Saccharomyces cerevisiae. Mol Cell Biol 17, 4718-4729. 
 
Zhang, S., Skalsky, Y., and Garfinkel, D.J. (1999). MGA2 or SPT23 is required for 
transcription of the delta9 fatty acid desaturase gene, OLE1, and nuclear membrane integrity 
in Saccharomyces cerevisiae. Genetics 151, 473-483. 
 
Zheng, H., You, H., Zhou, X.Z., Murray, S.A., Uchida, T., Wulf, G., Gu, L., Tang, X., Lu, K.P., 
and Xiao, Z.-X.J. (2002). The prolyl isomerase Pin1 is a regulator of p53 in genotoxic 
response. Nature 419, 849-853. 
 
 
 
 
Abbreviations 
80 
8 Abbreviations 
 
 
µ  micro (x10-6) 
2µ multi-copy vectors 
3-AT 3-aminotriazole 
AAA ATPases associated with various cellular activities 
AD Gal4 activation domain 
ANK Ankyrin repeat domain 
APC/C Anaphase promoting complex/cyclosome 
APS Ammonium peroxodisulphate 
ARS Autonomous replicating sequence 
ATP  Adenosine 5-triphosphate 
BD Gal4 DNA binding domain 
bp  Base pairs 
BSA  Bovine serum albumin 
CCD  Camera charged-coupled device camera 
cDNA  Complimentary DNA 
CEN Centromeric (low copy vectors) 
CHX Cycloheximide 
CK2 Casein kinase 2 
C-terminal  Carboxyl-terminal 
C-terminus  Carboxyl terminus 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium 
DMF N,N-dimethylformamide 
DMSO  Dimethylsulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  Deoxy nucleoside triphosphate 
DTT  Dithiothreitol 
DUB Deubiquitylating 
E1  Ubiquitin activation enzyme 
E2  Ubiquitin conjugation enzyme 
E3  Ubiquitin ligase 
E4  Polyubiquitylation factor 
EDTA  Ethylenediaminetetraacidic acid 
ER  Endoplasmic reticulum 
ERAD ER-associated degradation 
F Farad 
FCS Fetal calf serum 
g  Gram 
g  Gravitational constant (6.6742x10-11 N m2 kg-2) 
G418 Geniticin 
Gal  Galactosidase 
GFP Green fluorescent protein 
GRR gGycine-rich region 
GST Gutathion S-transferase 
h  Hours 
HECT Homologous to E6AP C-terminus 
HEPES N-(2-hydroxyethyl)-piperazin-N!-(2-ethansulfonate) 
IκB Inhibitor of κB 
Ig  Immunoglobulin 
IKK Inhibitor of κB Kinase 
IP  Immunoprecipitation 
IPT Immunoglobulin-like/plexins/transcription factors 
IVT Coupled in vitro transcription/translation 
Juglone 5-hydroxy-1,4-naphthoquinone 
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k  Kilo (x103) 
kan  Kanamycine 
kb  Kilo base pairs 
kDa  Kilo dalton 
LB  Luria-Bertani 
M  Molar 
m  Milli (x10-3) 
MAT  Mating type 
MG132 Proteasome inhibitor Z-Leu-Leu-Leu-al 
MHC Major histocompatibility complex 
min  Minutes 
MOPS  3-N-Morpholinopropane sulfonic acid 
mRNA  Messenger RNA 
MW  Molecular weight 
n  Nano (x10-9) 
NAT Nourseothricin 
NEM  N-ethylmaleimide ADP adenosine 5-diphosphate 
NEM N-ethyl maleimide 
NFκB Nuclear factor κB 
NiNTA Nickel-nitrilo triacetate 
NLS Nuclear localization sequence 
NP40 Nonyl phenoxylpolyethoxylethanol 
N-terminal  Amino-terminal 
N-terminus  Amino terminus 
OD Optical density  
ONPG o-Nitrophenyl-β-D-galactopyranosid 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PBS  Phosphate-buffered saline 
PCR  Polymerase chain reaction 
PefaBloc 4 -(2- Aminoethyl)-benzylsulfonylfluorid Hydrochlorid 
PEG  Polyethylene glycol 
PKA Protein kinase A 
PMSF Phenylmethylsulphonyl fluoride 
PVDF Polyvinylidene fluoride 
RING  Really interesting new gene 
RIP Regulated intramembrane proteolysis 
RNA Ribonucleic acid 
rpm  Rounds per minute 
RT  Room temperature 
RUD Ubiquitin/proteasome-dependent degradation 
RUP Ubiquitin/proteasome-dependent processing 
s Seconds 
S  Sedimentation coefficient (Svedberg) 
SC Synthetic complete medium 
SCF Skp1-Cul1-F-box complex 
SDS  Sodium dodecylsulfate   
TAD Transactivation domain 
TBB CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole 
TBE Tris/borate/EDTA buffer 
TBS  Tris-buffered saline 
TCA  Trichloro acidic acid 
TEMED N,N,Nʼ,Nʼ-tetramethylethylenediamin 
TM Transmembrane 
Tris Tris(hydroxymethyl)aminomethane 
U Unit 
Ub Ubiquitin 
UBA Ubiquitin associated 
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UBC Ubiquitin conjugating enzyme 
UCH Ubiquitin C-terminal Hydrolase 
UFA Unsaturated fatty acid 
UFD Ubiquitin fusion degradation 
UIM Ubiquitin interacting motif 
UPS  Ubiquitin/proteasome system 
UV Ultraviolet light 
V Volt 
v/v Volume per volume 
w/v Weight per volume 
WT Wild-type 
YPD Yeast bactopeptone dextrose medium 
Ω Ohm 
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